[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 5018
1. Muñoz Llarena A, Carrera Revilla S, Gil-Negrete Laborda A, Pac Ferrer J, Barceló Galíndez R, López Vivanco G: [Prognostic factors associated with resectable pulmonary metastases from colorectal cancer]. Arch Bronconeumol; 2007 Jun;43(6):309-16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic factors associated with resectable pulmonary metastases from colorectal cancer].
  • [Transliterated title] Factores pronósticos en metástasis pulmonares resecables de carcinoma colorrectal.
  • OBJECTIVE: To analyze prognostic factors associated with survival in a group of patients who underwent resection of pulmonary metastases from colorectal cancer.
  • PATIENTS AND METHODS: A retrospective review was performed for 55 consecutive patients who had undergone resection of pulmonary metastases from colorectal adenocarcinoma between January 1993 and June 2004.
  • Survival was lower in patients in whom the largest metastasis was at least 4 cm (8.6 vs 34.5 months, P=.0085) and in patients with elevated levels of carcinoembryonic antigen (24.5 vs 41.4 months, P=.05).
  • Preoperative positron emission tomography (PET) and the absence of previous or synchronous liver metastases were associated with a nonsignificant trend toward increased survival.
  • In the multivariate analysis, only size of the largest pulmonary metastasis influenced overall survival (P=.036).
  • CONCLUSIONS: The preoperative variables that best predicted survival in our patients were size of the largest pulmonary metastasis and the level of carcinoembryonic antigen.
  • Prospective studies are needed to determine the usefulness of PET for tumor staging prior to resection of pulmonary metastases.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / secondary. Colorectal Neoplasms / pathology. Lung Neoplasms / mortality. Lung Neoplasms / secondary

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17583640.001).
  • [ISSN] 0300-2896
  • [Journal-full-title] Archivos de bronconeumología
  • [ISO-abbreviation] Arch. Bronconeumol.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 30
  •  go-up   go-down


2. Chen F, Miyahara R, Bando T, Okubo K, Watanabe K, Nakayama T, Toguchida J, Date H: Repeat resection of pulmonary metastasis is beneficial for patients with osteosarcoma of the extremities. Interact Cardiovasc Thorac Surg; 2009 Oct;9(4):649-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Repeat resection of pulmonary metastasis is beneficial for patients with osteosarcoma of the extremities.
  • Pulmonary metastasectomy in osteosarcoma can lead to long-term survival, but the role for repeat pulmonary metastasectomy is undefined.
  • To confirm the value of repeat pulmonary resection of recurrent pulmonary metastases, we herein reviewed our institutional experience.
  • Between 1989 and 2007, 25 patients with pulmonary metastases from osteosarcomas of the extremities underwent pulmonary resection, and 14 patients underwent repeat pulmonary metastasectomy.
  • Various perioperative variables were investigated retrospectively in these patients to confirm a role for repeat metastasectomy and analyze prognostic factors for overall survival (OS) after repeat pulmonary metastasectomy.
  • OS rate after repeat pulmonary metastasectomy was 43% at two years and 19% at five years.
  • Interestingly enough, survival curve of patients with complete resection after the first pulmonary metastasectomy was almost the same as that of patients with complete resection after the second pulmonary metastasectomy.
  • In conclusion, patients with complete resection for recurrent pulmonary metastasis show a significantly better prognosis after repeat pulmonary metastasectomy.
  • Our data imply that repeat pulmonary metastasectomy might be beneficial because it can salvage a subset of patients with osteosarcoma who retain favorable prognostic determinants.
  • [MeSH-major] Bone Neoplasms / pathology. Lung Neoplasms / surgery. Osteosarcoma / surgery. Pneumonectomy


3. Mochizuki T, Okumura S, Ishii G, Ishikawa Y, Hayashi R, Kawabata K, Yoshida J: Surgical resection for oral tongue cancer pulmonary metastases. Interact Cardiovasc Thorac Surg; 2010 Jul;11(1):56-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical resection for oral tongue cancer pulmonary metastases.
  • The aim of this study was to evaluate the efficacy of surgical resection of oral tongue cancer (OTC) pulmonary metastases.
  • Between 1977 and 2003, 23 OTC patients who developed 1-3 pulmonary metastases underwent metastasectomy.
  • There were 14 men and nine women with a median age at the time of first metastasectomy of 56 years.
  • All patients had advanced squamous cell OTC with synchronous or metachronous regional lymph node metastases.
  • The median tumor-free interval after the last OTC treatment was 12 months.
  • Two patients underwent a second pulmonary metastasectomy.
  • Twenty-two out of 23 patients developed systemic metastases.
  • The median interval to systemic recurrence after lung resection was 4.1 months, and 21 out of 23 patients died of OTC (median, 9.5 months) after metastasectomy.
  • Most patients who underwent pulmonary metastasectomy died of the disease within two years of metastasectomy.
  • Even for patients with a solitary metastasis, surgical metastasectomy is not a recommended treatment option.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / surgery. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Pneumonectomy. Tongue Neoplasms / pathology

  • Genetic Alliance. consumer health - Oral cancer.
  • Genetic Alliance. consumer health - Tongue cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20357009.001).
  • [ISSN] 1569-9285
  • [Journal-full-title] Interactive cardiovascular and thoracic surgery
  • [ISO-abbreviation] Interact Cardiovasc Thorac Surg
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


Advertisement
4. Zhang SM, Zeng ZC, Tang ZY, Sun J, Cheng JM, Liu R, Wang P, Zhang BH: Prognostic analysis of pulmonary metastases from hepatocellular carcinoma. Hepatol Int; 2008 Jun;2(2):237-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic analysis of pulmonary metastases from hepatocellular carcinoma.
  • PURPOSE: To analyze the prognostic factors for the patients with lung metastases from hepatocellular carcinoma (HCC).
  • METHODS AND MATERIALS: One hundred and five patients with lung metastases from HCC were analyzed retrospectively.
  • We analyzed the impact factors, including the gender, age, liver function, serum AFP and gamma-GT level, the status of intrahepatic tumor and pulmonary metastases and treatment for them, the distant metastases beyond the lung, as well as the causes of death.
  • RESULT: The survival after the lung metastases was influenced by clinical parameters, such as the status and the treatment for both the intrahepatic tumor and the pulmonary lesions.
  • The causes of death were respiratory failure due to metastatic lesions from HCC in 16 patients (20.0%), liver failure caused by the progressive intrahepatic lesions in 54 (67.5%).
  • The mean and median survival times were 684 and 487 days after HCC diagnosis and 264 and 179 days after lung metastases, respectively.
  • CONCLUSION: It was very important to treat the intrahepatic tumor because its worsening was still the major cause of death.
  • The progressive treatment for pulmonary metastases may also be advised for possible prolongation of survival.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Ultrasound. 2001 Jun;13(2):167-76 [11369528.001]
  • [Cites] Surg Oncol. 2001 Jul-Aug;10(1-2):35-42 [11719027.001]
  • [Cites] World J Gastroenterol. 2002 Apr;8(2):193-9 [11925590.001]
  • [Cites] Cancer J. 2004 Sep-Oct;10(5):307-16 [15530260.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):432-43 [15667964.001]
  • [Cites] Br J Surg. 1998 Sep;85(9):1198-200 [9752858.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 1999 Jul;21(4):245-9 [11776805.001]
  • [Cites] Jpn J Clin Oncol. 2005 Feb;35(2):61-7 [15709088.001]
  • (PMID = 19669310.001).
  • [ISSN] 1936-0533
  • [Journal-full-title] Hepatology international
  • [ISO-abbreviation] Hepatol Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2716849
  •  go-up   go-down


5. Fernando HC: Radiofrequency ablation to treat non-small cell lung cancer and pulmonary metastases. Ann Thorac Surg; 2008 Feb;85(2):S780-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiofrequency ablation to treat non-small cell lung cancer and pulmonary metastases.
  • Radiofrequency ablation is being reported with increasing frequency for the treatment of lung tumors.
  • This review describes the techniques, available ablation devices, and the potential role of radiofrequency ablation for non-small cell lung cancer (NSCLC) and pulmonary metastases.
  • Preliminary results for pulmonary metastases are similar to those reported after resection.
  • In addition, patients with pulmonary metastases have been demonstrated to develop recurrences even after thoracotomy and bimanual palpation of the lung.
  • Radiofrequency ablation may be an alternative to resection for the patient with small-diameter pulmonary metastases, and future study of this may be indicated.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / secondary. Carcinoma, Non-Small-Cell Lung / surgery. Catheter Ablation / methods. Lung Neoplasms / secondary. Lung Neoplasms / surgery
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Male. Middle Aged. Minimally Invasive Surgical Procedures / methods. Neoplasm Invasiveness / pathology. Neoplasm Metastasis. Neoplasm Staging. Patient Selection. Risk Assessment. Sex Factors. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Thorac Surg. 2009 Jul;88(1):351-2 [19559273.001]
  • (PMID = 18222217.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 30
  •  go-up   go-down


6. Takahashi S, Nagai K, Saito N, Konishi M, Nakagohri T, Gotohda N, Nishimura M, Yoshida J, Kinoshita T: Multiple resections for hepatic and pulmonary metastases of colorectal carcinoma. Jpn J Clin Oncol; 2007 Mar;37(3):186-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple resections for hepatic and pulmonary metastases of colorectal carcinoma.
  • BACKGROUND: Resections are effective for some patients with both hepatic and pulmonary metastases of colorectal cancer, but the best selection criteria for the resections and effective treatment for recurrence after the resections have not been determined.
  • METHODS: A retrospective analysis was performed for 30 consecutive patients who received aggressive multiple resections for both hepatic and pulmonary metastases of colorectal cancer.
  • RESULTS: For the 30 patients, 45 hepatectomies and 40 pulmonary resections were performed and 17 patients received three or more resections.
  • Overall survival after the first metastasectomy for the second organ (liver or lung) was 58% and nine 5-year survivors were observed.
  • Multivariate analyses revealed that primary colon cancer, stage IV in TNM classification and maximum size of hepatic tumor >3 cm at initial hepatectomy were poor prognostic factors, but several long-term survivors were observed even among patients with those factors.
  • CONCLUSIONS: Multiple resections for hepatic and pulmonary metastases of colorectal cancer are safe and effective.
  • [MeSH-major] Colorectal Neoplasms / pathology. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Lung Neoplasms / secondary. Lung Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Female. Hepatectomy. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local / surgery. Pneumonectomy. Prognosis. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17472970.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


7. Yu JJ, Robb VA, Morrison TA, Ariazi EA, Karbowniczek M, Astrinidis A, Wang C, Hernandez-Cuebas L, Seeholzer LF, Nicolas E, Hensley H, Jordan VC, Walker CL, Henske EP: Estrogen promotes the survival and pulmonary metastasis of tuberin-null cells. Proc Natl Acad Sci U S A; 2009 Feb 24;106(8):2635-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estrogen promotes the survival and pulmonary metastasis of tuberin-null cells.
  • Lymphangioleiomyomatosis (LAM) is an often fatal disease primarily affecting young women in which tuberin (TSC2)-null cells metastasize to the lungs.
  • We report here that 17-beta-estradiol (E(2)) causes a 3- to 5-fold increase in pulmonary metastases in male and female mice, respectively, and a striking increase in circulating tumor cells in mice bearing tuberin-null xenograft tumors.
  • E(2)-induced metastasis is associated with activation of p42/44 MAPK and is completely inhibited by treatment with the MEK1/2 inhibitor, CI-1040.
  • Finally, using a bioluminescence approach, we found that E(2) enhances the survival and lung colonization of intravenously injected tuberin-null cells by 3-fold, which is blocked by treatment with CI-1040.
  • Taken together these results reveal a new model for LAM pathogenesis in which activation of MEK-dependent pathways by E(2) leads to pulmonary metastasis via enhanced survival of detached tuberin-null cells.
  • [MeSH-major] Cell Survival / physiology. Estrogens / physiology. Lung Neoplasms / pathology. Tumor Suppressor Proteins / physiology
  • [MeSH-minor] Animals. Anoikis / physiology. Benzamides / pharmacology. Carrier Proteins / antagonists & inhibitors. Female. Mice. Mitogen-Activated Protein Kinases / antagonists & inhibitors. Neoplasm Metastasis. Ovariectomy. Phosphotransferases (Alcohol Group Acceptor) / antagonists & inhibitors. Rats. TOR Serine-Threonine Kinases


8. Agrawal A: Chondroid chordoma of petrous temporal bone with extensive recurrence and pulmonary metastases. J Cancer Res Ther; 2008 Apr-Jun;4(2):91-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chondroid chordoma of petrous temporal bone with extensive recurrence and pulmonary metastases.
  • Chordoma rarely metastasizes but it is, nevertheless, associated with a poor outcome.
  • We report a rare case of chondroid chordoma with extensive recurrence and pulmonary metastases.
  • [MeSH-major] Chordoma / pathology. Lung Neoplasms / secondary. Petrous Bone / pathology. Skull Neoplasms / pathology. Temporal Bone / pathology
  • [MeSH-minor] Adult. Cranial Nerve Diseases / physiopathology. Fatal Outcome. Humans. Male. Neoplasm Metastasis / pathology. Neoplasm Metastasis / radiotherapy. Pneumonia / complications. Radiography, Thoracic. Recurrence

  • Genetic Alliance. consumer health - Chordoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18688126.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


9. White DC, D'Amico TA: Radiofrequency ablation for primary lung cancer and pulmonary metastases. Clin Lung Cancer; 2008 Jan;9(1):16-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiofrequency ablation for primary lung cancer and pulmonary metastases.
  • Lung cancer remains one of the leading causes of death throughout the world.
  • Although surgery is the gold standard treatment for lung cancer, the majority of patients are not resectable at the time of diagnosis.
  • Even among patients who are potentially resectable, many are treated nonoperatively because of inadequate pulmonary reserve or advanced comorbidities.
  • Radiofrequency ablation can be applied to primary pulmonary malignancies and metastatic lesions and is reported to achieve excellent local control in limited clinical series.
  • Human and animal studies supporting the use of radiofrequency ablation for pulmonary malignancy are reviewed, and the current application of radiofrequency ablation and its limitations are described herein.
  • [MeSH-major] Catheter Ablation / methods. Lung Neoplasms / secondary. Lung Neoplasms / surgery
  • [MeSH-minor] Animals. Carcinoma, Non-Small-Cell Lung / surgery. Humans. Positron-Emission Tomography. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18282353.001).
  • [ISSN] 1525-7304
  • [Journal-full-title] Clinical lung cancer
  • [ISO-abbreviation] Clin Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 49
  •  go-up   go-down


10. Tsukamoto G, Ibaragi S, Shimo T, Oyama K, Kishimoto K, Mese H, Aoe M, Kiura K, Sasaki A: [A successful case of lower gingival cancer with pulmonary metastases by adjuvant chemotherapy including paclitaxel, cisplatin and 5-fluorouracil following a surgical procedure]. Gan To Kagaku Ryoho; 2007 Apr;34(4):597-600
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A successful case of lower gingival cancer with pulmonary metastases by adjuvant chemotherapy including paclitaxel, cisplatin and 5-fluorouracil following a surgical procedure].
  • We report a successful case with pulmonary metastases from lower gingival cancer by a surgical procedure and four cycles of adjuvant chemotherapy including paclitaxel (PTX), cisplatin (CDDP) and 5-fluorouracil (5-FU).
  • A 47-year-old woman underwent chemotherapy with CDDP and 5-FU after an operation for lower gingival squamous cell carcinoma and its neck lymph node metastases.
  • At 4 months from the initial treatment, pulmonary metastatic lesion was resected by video-assisted thoracoscopic surgery (VATS).
  • Fourteen months later, pulmonary metastatic lesion was found and dissected again using VATS.
  • After that, there is no evidence of pulmonary recurrence for more than six years.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Gingival Neoplasms / drug therapy. Lung Neoplasms / secondary. Lymph Nodes / pathology. Pneumonectomy / methods
  • [MeSH-minor] Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Humans. Lymphatic Metastasis. Middle Aged. Paclitaxel / administration & dosage. Remission Induction. Thoracic Surgery, Video-Assisted

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17431347.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


11. Cruz J, Felizardo M, Silva J, Monteiro F, Rodrigues T, Caldeira J, Costa L, Cravino J: [Surgery of pulmonary metastasis]. Rev Port Cir Cardiotorac Vasc; 2008 Jan-Mar;15(1):15-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgery of pulmonary metastasis].
  • [Transliterated title] Cirurgia das metáses pulmonares.
  • Between April 1993 and December 2007, 92 patients underwent the complete resection of pulmonary metastases, 47 mens (51.1%) and 45 womens (49.9%).
  • 26 patients (27.2%) had solitary pulmonary metastasis, 25 (26.1%) multiple pulmonary metastasis and 41 (44.5%) patients presented bilateral pulmonary metastasis.
  • 42 patients (45.6%) presented pulmonary metastasis recurrence, 14 patients (15.2%) a second recurrence and 6 patients (6.5%) a third pulmonary metastasis recurrence.
  • CONCLUSION: Thys work demonstrated that every attempt should be made to completely ressect all clinically detected metastases.
  • Complete resection of pulmonary metastasis, even in recurrent disease is compatible with long-term survival.
  • [MeSH-major] Lung Neoplasms / secondary. Lung Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18618046.001).
  • [ISSN] 0873-7215
  • [Journal-full-title] Revista portuguesa de cirurgia cardio-torácica e vascular : órgão oficial da Sociedade Portuguesa de Cirurgia Cardio-Torácica e Vascular
  • [ISO-abbreviation] Rev Port Cir Cardiotorac Vasc
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Portugal
  •  go-up   go-down


12. Tsukioka T, Nishiyama N, Iwata T, Nagano K, Izumi N, Mizuguchi S, Morita R, Inoue K, Suehiro S: Pulmonary metastasis from colorectal carcinoma with hepatic metastasis. Gen Thorac Cardiovasc Surg; 2007 Nov;55(11):455-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary metastasis from colorectal carcinoma with hepatic metastasis.
  • OBJECTIVE: Although some beneficial effects of surgical treatments for pulmonary or hepatic metastases from colorectal carcinoma have been reported, identifying candidates for these aggressive surgical procedures is controversial.
  • In this study, patients with pulmonary metastases from colorectal carcinoma, particularly those with pulmonary and hepatic metastases, were retrospectively analyzed.
  • METHODS: Forty-six patients who had undergone complete resection for pulmonary metastases from colorectal carcinoma were retrospectively analyzed.
  • RESULTS: The median follow-up period after pulmonary resection was 26 months, and the 5-year postoperative survival rate was 34%.
  • The 5- and 10-year survival rates of patients with pulmonary metastasis alone, metachronous pulmonary metastasis after liver metastasis, and synchronous metastasis to the liver and lung were 75%, 75%, and 25% and 25%, 38%, and 0%, respectively, when calculated from the time of primary colorectal resection (P < 0.01).
  • Patients with synchronous metastases had a poorer prognosis than did the patients in the other two groups.
  • CONCLUSIONS: Surgical treatments for patients with pulmonary metastasis alone or metachronous metastasis can provide a beneficial outcome.
  • Patients with synchronous metastasis have a poor prognosis, and effective pre- and postoperative systemic treatments should be considered to prolong their survival.
  • [MeSH-major] Colorectal Neoplasms / pathology. Liver Neoplasms / pathology. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18049853.001).
  • [ISSN] 1863-6705
  • [Journal-full-title] General thoracic and cardiovascular surgery
  • [ISO-abbreviation] Gen Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


13. Kaya M, Wada T, Nagoya S, Yamashita T: Prevention of postoperative progression of pulmonary metastases in osteosarcoma by antiangiogenic therapy using endostatin. J Orthop Sci; 2007 Nov;12(6):562-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevention of postoperative progression of pulmonary metastases in osteosarcoma by antiangiogenic therapy using endostatin.
  • BACKGROUND: We have previously offered data suggesting a positive linkage of postoperative up-regulation of systemic angiogenic activity and postoperative progression of pulmonary metastasis in osteosarcoma.
  • The finding that the significant down-regulation of endostatin was critical in angiogenic elevation after primary tumor removal suggests that endostatin is a candidate for antiangiogenic therapy for osteosarcoma.
  • METHODS: In the current study, we evaluated the effect of antiangiogenic therapy using endostatin on postoperative progression of pulmonary metastasis from osteosarcoma.
  • Two weeks after tumor inoculation, the primary tumor was removed surgically, and antiangiogenic therapy using adenovirus encoding endostatin expression vector (Ad5CMV-mEnd) was performed.
  • Two weeks after the antiangiogenic treatment, pulmonary metastasis was evaluated by counting the number of metastatic nodules.
  • RESULTS: Two weeks after the viral injection, mice were sacrificed, and the macroscopic pulmonary metastases were counted.
  • Notably, the number of pulmonary metastases was smaller in the mice injected with Ad5CMV-mEnd than in controls, accompanied by significant suppression of systemic angiogenic activity.
  • In addition, the sizes of the pulmonary metastases of the mice injected with Ad5CMV-mEnd were smaller than in the control group.
  • CONCLUSIONS: Our results indicate that antiangiogenic therapy using endostatin has the potential to prevent postoperative progression of pulmonary metastasis from osteosarcoma.
  • Although this therapeutic strategy cannot provide a cure for osteosarcoma, it should enable osteosarcoma patients to coexist with dormant pulmonary metastasis and lead to improvement of their prognosis.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Bone Neoplasms / surgery. Endostatins / therapeutic use. Lung Neoplasms / drug therapy. Neoplasms, Experimental / surgery. Osteosarcoma / drug therapy
  • [MeSH-minor] Animals. Cell Line, Tumor. Disease Progression. Enzyme-Linked Immunosorbent Assay. Female. Mice. Mice, Inbred BALB C. Neoplasm Metastasis. Neovascularization, Pathologic / blood. Neovascularization, Pathologic / drug therapy. Neovascularization, Pathologic / pathology. Postoperative Period

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18040639.001).
  • [ISSN] 0949-2658
  • [Journal-full-title] Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association
  • [ISO-abbreviation] J Orthop Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Endostatins
  •  go-up   go-down


14. Rodrigo-Garzón M, Berraondo P, Ochoa L, Zulueta JJ, González-Aseguinolaza G: Antitumoral efficacy of DNA nanoparticles in murine models of lung cancer and pulmonary metastasis. Cancer Gene Ther; 2010 Jan;17(1):20-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antitumoral efficacy of DNA nanoparticles in murine models of lung cancer and pulmonary metastasis.
  • Polyethylenimine (PEI)-DNA complexes are nanoparticles that are able to efficiently transfer plasmids to the lungs.
  • Interleukin-12 (IL12) gene transfer using PEI may represent an important strategy for lung cancer treatment.
  • In this study, we evaluated the antitumoral efficacy of the administration of PEI-DNA nanoparticles carrying IL12 gene (PEI-IL12) for the treatment of lung cancer and pulmonary metastases in animal models.
  • After inoculation of tumor cells, mice were treated intravenously with a single dose of PEI-IL12, PEI nanoparticles carrying the reporter gene beta-galactosidase (PEI-LacZ) or vehicle.
  • Administration of PEI-LacZ and PEI-IL12 nanoparticles controlled tumor growth and prolonged survival times in both animal models.
  • Although PEI-IL12 and PEI-LacZ administration showed similar antitumoral effects in the lung cancer model, the efficacy of PEI-IL12 was significantly superior in the inhibition of the development of pulmonary metastases.
  • Our results showed that PEI-DNA nanoparticles are an efficient vector for mediating gene transfer to the lungs, are a potent inducer of the innate immune response and represents an interesting strategy for the treatment of bronchogenic carcinoma and metastatic lung carcinoma.
  • [MeSH-major] DNA / administration & dosage. Genetic Therapy / methods. Interleukin-12 / genetics. Lung Neoplasms / therapy. Nanoparticles / administration & dosage

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19575045.001).
  • [ISSN] 1476-5500
  • [Journal-full-title] Cancer gene therapy
  • [ISO-abbreviation] Cancer Gene Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 187348-17-0 / Interleukin-12; 9002-98-6 / Polyethyleneimine; 9007-49-2 / DNA
  •  go-up   go-down


15. Tomimaru Y, Sasaki Y, Yamada T, Eguchi H, Takami K, Ohigashi H, Higashiyama M, Ishikawa O, Kodama K, Imaoka S: The significance of surgical resection for pulmonary metastasis from hepatocellular carcinoma. Am J Surg; 2006 Jul;192(1):46-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The significance of surgical resection for pulmonary metastasis from hepatocellular carcinoma.
  • BACKGROUND: Pulmonary metastasis, which is the most common type of extrahepatic recurrence of hepatocellular carcinoma (HCC), has been considered unsuitable for surgical resection because most pulmonary metastases are multiple.
  • Until now there have been few reports about surgical resection for pulmonary metastasis from HCC.
  • The aim of the present study was to evaluate the significance of surgical resection for pulmonary metastasis from HCC.
  • METHODS: Among 615 patients who underwent radical hepatic resection for HCC in our hospital over the past 15 years, 8 patients who had developed 1 or 2 pulmonary metastases underwent pulmonary resection for the pulmonary metastases (resection group), the other 6 patients who had developed 1 or 2 pulmonary metastases did not undergo pulmonary resection (nonresection group).
  • The clinicopathologic features and long-term prognosis of the resection group were examined and compared with those of the nonresection group.
  • RESULTS: In the resection group, although intrahepatic recurrences were present before the diagnosis of pulmonary metastasis in 4 patients, they were well controlled by repeated transarterial chemoembolization and/or further hepatic resections.
  • The average survival periods after the pulmonary resection and after the initial hepatic resection were 29 months (range, 5-80 mo) and 61 months (range, 24-133 mo), respectively.
  • No patients in the resection group showed pulmonary recurrence after the pulmonary resection, and the cause of death of the patients in the resection group was not pulmonary metastasis.
  • CONCLUSIONS: It may be concluded that surgical resection for pulmonary metastasis from HCC might be beneficial in selected patients.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Liver Neoplasms / pathology. Lung Neoplasms / surgery. Pneumonectomy

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16769274.001).
  • [ISSN] 0002-9610
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Liang JW, Zhou ZX, Liu Q, Bi JJ, Wang Z, Zhang XM, Zhao P: [Prognostic factors of resectable pulmonary metastases from colorectal cancer]. Zhonghua Zhong Liu Za Zhi; 2010 Sep;32(9):694-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic factors of resectable pulmonary metastases from colorectal cancer].
  • OBJECTIVE: To evaluate the prognostic factors for patients who underwent curative resection of pulmonary metastases from colorectal cancer.
  • METHODS: The clinicopathological data of 60 patients with pulmonary metastases from colorectal carcinoma who underwent a radical pulmonary metastasectomy between February 1985 and December 2004 at the Cancer Hospital of Chinese Academy of Medical Sciences were retrospectively reviewed and analyzed.
  • RESULTS: The overall 5-year survival rate was 43.7% after pulmonary excision and 74.0% after colorectal resection.
  • Three factors were identified as significant by univariate log-rank test for overall survival after pulmonary resection, they were preoperative carcinoembryonic antigen, number of pulmonary metastases (solitary vs. multiple), and hilar and/or mediastinal lymph node metastases (P < 0.05).
  • Multivariate analysis showed that number of pulmonary metastases (solitary vs. multiple) and hilar and/or mediastinal lymph node metastasis were independent prognostic factors.
  • However, shorter disease-free interval and more number of pulmonary metastases predicted poor prognosis after primary colorectal resection.
  • CONCLUSION: Pulmonary resection for metastases from colorectal cancer is safe and patients may get long-term survival in selected cases, especially in patients with a solitary pulmonary metastasis and without hilar and/or mediastinal lymph node metastasis.
  • [MeSH-major] Colonic Neoplasms / surgery. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Rectal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Carcinoembryonic Antigen / blood. Colectomy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Pneumonectomy / methods. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21122386.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  •  go-up   go-down


17. Gyergyay F, Nagyványi K, Bodrogi I: Decreased toxicity schedule of suitinib in renal cell cancer: 2 weeks on/1 week off. J Clin Oncol; 2009 May 20;27(15_suppl):e16113
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased toxicity schedule of suitinib in renal cell cancer: 2 weeks on/1 week off.
  • : e16113 Background: Sunitinib (SU) is an oral multitargeted tyrosine kinase inhibitor of VEGFRs, PDGFRs, KIT, FLT3, CSF-1R and RET approved for treatment of metastatic renal cell cancer (mRCC).
  • RESULTS: Of 36 pts, median age 59.5 yrs (range 42-83), M/F (26:10), ECOG: 0 (21); 1 (9); 2 (6); prior nephrectomy (35),prior radiation therapy (28), prior cytokine therapy: IFNα (25), IL-2+IFNα (9) none (2); pts with 1 metastatic organ (24); 2 metastatic sites (7); ≥ 3 sites (5); Sites of metastases: Lung (27), Bone (11), Liver (3); MSCC risk factors: 0 (20), 1-2 (14); ≥3 (2).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963329.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Ladenstein R, Pötschger U, Le Deley M, Whelan J, Paulussen M, Oberlin O, van der Berg H, Dirksen U, Craft A, Jürgens H: A prognostic score at diagnosis for Ewing tumor patients with metastatic disease at extrapulmonary sites. J Clin Oncol; 2009 May 20;27(15_suppl):10544
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prognostic score at diagnosis for Ewing tumor patients with metastatic disease at extrapulmonary sites.
  • : 10544 Background: To assess prognostic factors at diagnosis in prospectively treated patients with primary extra-pulmonary metastatic Ewing tumors (EPM-ET) of the EURO-E.W.I.N.G. 99 Study.
  • Primary site was extremity in 84 patients and axial in 197 (115 pelvic sites), with a tumor volume >200ml in 171 patients.
  • Cox regression analyses demonstrated increased risk for patients with more than two bone metastatic sites (hazard ratio: HR 2.0), a primary tumor volume >200ml (HR 1.8), bone marrow metastases (HR 1.6), age >14 years (HR 1.6), and additional lung metastases (HR 1.5).
  • Age, tumor volume, and extent of metastatic spread are relevant risk factors.
  • A score based on these factors identifies EPMD-ET patients with a more favorable outlook at diagnosis and may facilitate risk adapted treatment approaches.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963951.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Osako T, Nishimura R, Okumura Y, Hayashi M: Current status of treatment of local recurrence and distant metastasis of triple negative breast cancer in Japanese population. J Clin Oncol; 2009 May 20;27(15_suppl):e11548
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current status of treatment of local recurrence and distant metastasis of triple negative breast cancer in Japanese population.
  • : e11548 Background: Triple-negative breast cancers have an aggressive clinical history such as high incidence of visceral metastases, high rate of cerebral metastases, high rate of local recurrence, and early age of onset.
  • However, there are limited long-term clinical data evaluating outcomes of locoregional and systemic therapy.
  • METHODS: From the medical records of our hospital, we retrospectively reviewed breast cancer patients whose three markers were available and describe the relationship between current therapy and clinical outcome.
  • RESULTS: Between 1998 and 2007, 1967 breast cancer patients were treated in Kumamoto City Hospital.
  • As of December 2008, with a median follow-up time of 31months, 53 patients (20.0%) with TNBC had locoregional recurrences or distant metastases (17 local recurrences, 15 nodal recurrences, 44 distant metastases).
  • Of 53 patients with recurrences, 31 had initial locoregional recurrence and 19 had initial distant metastases.
  • Forty two patients had already been dead and common causes of death were lung metastases (19 patients), liver metastases (11 patients), and brain metastases (8 patients).
  • Furthermore, patients with initial distant metastases had significantly poorer survival than those with initial locoregional recurrence (p=0.015).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964664.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Adolph MD, Taylor RM, Ross PM, Vaida AM, Moffatt-Bruce SD: Evaluating cancer patient satisfaction before and after daily multidisciplinary care for thoracic surgery inpatients. J Clin Oncol; 2009 May 20;27(15_suppl):9605
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluating cancer patient satisfaction before and after daily multidisciplinary care for thoracic surgery inpatients.
  • : 9605 Background: Significant subpopulations of cancer inpatients in the SUPPORT trial were dissatisfied with their pain control. (Desbiens, Wu et al.
  • 1996) The hospitalized thoracic surgical patient is a person at risk for uncontrolled symptoms and burdens due to advanced cancer at time of presentation.
  • METHODS: This is a retrospective, observational, study of 1188 thoracic surgery patients undergoing elective surgical procedures for lung cancer at an NCI-approved cancer hospital over a 3-year period.
  • Patients with primary and secondary lung cancer, undergoing elective thoracic surgery procedures were evaluated before (n=660, "Period 1") and after (n=528, "Period 2") an 8-month, daily, collaborative multidisciplinary Intervention Period to improve pain control and to facilitate transition for discharge.
  • The collaborative relationship resulted in an increase in referrals to hospice for patients with advanced cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963839.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Dutour A, Decouveleare A, Josserand V, Coll J, Chotel F, Rousseau R: Improving the detection of osteosarcoma tumor margins and metastasis using diagnostic nanoparticles. J Clin Oncol; 2009 May 20;27(15_suppl):10512
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improving the detection of osteosarcoma tumor margins and metastasis using diagnostic nanoparticles.
  • : 10512 Background: The aim of osteosarcoma resection is the complete removal of the primary malignant lesion with adequate margins taking into account tumor control and functional reconstruction.
  • To date, no intraoperative method is available to assist surgeons in precisely delineating tumor extension in the adjacent normal tissues.
  • We developed fluorescent nanoparticles RAFT-cRGD<sub>4</sub>-ICG' targeting αVβ3 integrins on tumor neovessels and demonstrated their capacity to reveal tumor and its margins when exposed to near infrared (NIR) light.
  • METHODS: We evaluated in an orthotopic metastatic osteosarcoma in rats the potential of RAFT-cRGD<sub>4</sub>-ICG' detected intra operatively by NIR illumination to improve margin resection without compromising local tumor control.
  • Controls consisted of pathological margin analysis of the resected tumor/metastasis comparing ICG' fluorescence with conventional tissue coloration, and pre operative magnetic resonance imaging.
  • RESULTS: We showed a significantly lesser extent of healthy tissue resection after surgical excision when assessing tumor margin intra operatively using RAFT-cRGD<sub>4</sub>-ICG' and NIR camera compared to preoperative imaging studies and post operative conventional pathology coloration (p<0.01).
  • Importantly, intraoperative NIR illumination of lungs revealed more metastases than by intraoperative manual lung palpation (p<0.01).
  • CONCLUSIONS: Our preclinical data confirm the potential of intraoperative imaging for improved primary tumor and lung metastasis excision.
  • We are now generating clinical-grade RAFT-cRGD<sub>4</sub>-ICG' to further evaluate this approach as a mean to improve functional outcome after surgical excision while maintaining tumor control in patients with relapsed/metastatic osteosarcoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963647.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Alaoui-Jamali MA Sr, Gupta A, Szarek WA, Bismar TA, Gheorghe R, Schipper HM: A novel selective therapeutic targeting heme oxygenase-1 revealed a potent antimetastatic activity in androgen-refractory human prostate cancer models. J Clin Oncol; 2009 May 20;27(15_suppl):e16090
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel selective therapeutic targeting heme oxygenase-1 revealed a potent antimetastatic activity in androgen-refractory human prostate cancer models.
  • : e16090 Prostate cancer is a highly prevalent disease.
  • Despite a significant improvement in the overall survival attributed in part to early detection and introduction of novel therapeutic modalities, many cancer patients at primary diagnosis present advanced disease or experience recurrence of the cancer.
  • The progression of prostate cancer (PCA) to hormone-refractory phenotype (HRPCA) and to metastasis is an ominous event in patients with advanced PCA.
  • In this study, we identified heme oxygenase 1 (HO-1) to be significantly upregulated in epithelial PCA cells, but not in surrounding stromal cells, from hormone refractory prostate cancer cases compared to hormone-responsive prostate cancer and to benign tissues.
  • Specifically, inhibition of HO-1 gene in androgen-independent and highly invasive prostate cancer cells, PC3M, decreased HO-1 activity, oxidative stress, MAPKs activation, cell proliferation, and cell migration and invasion in vitro, as well as inhibition of prostate tumor growth and lymph nodes and lung metastases in vivo.
  • The impact of HO-1 silencing on these oncogenic features was mimicked by exposure of cells to a novel selective small-molecule HO-1 inhibitor referred to as OB-24.
  • OB-24 selectively downregulates HO-1 activity, oxidative stress, and significantly inhibits cell proliferation in vitro and tumor growth and lymph node/lung metastases in vivo.
  • A potent synergistic activity in inhibiting HRPCA metastasis formation was observed when OB-24 was combined with the chemotherapy drug taxol.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963085.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Carden CP, Frentzas S, Langham M, Casamayor I, Stephens AW, Poondru S, Wheaton J, Lippman SM, Kaye SB, Kim ES: Preliminary activity in adrenocortical tumor (ACC) in phase I dose escalation study of intermittent oral dosing of OSI-906, a small-molecule insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase inhibitor in patients with advanced solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):3544
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preliminary activity in adrenocortical tumor (ACC) in phase I dose escalation study of intermittent oral dosing of OSI-906, a small-molecule insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase inhibitor in patients with advanced solid tumors.
  • : 3544 Background: IGF-1R is overexpressed in various malignancies, and implicated in proliferation, survival, and metastasis.
  • IGF-1R blockade increases apoptosis and reduces tumor growth in preclinical models.
  • METHODS: Patients (pt) with advanced solid tumours were enrolled to determine safety, tolerability, maximum tolerated dose, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumor activity.
  • Of 3 pt with ACC, 1 pt had a partial response (43% reduction in primary and multiple lung metastases) and remains on treatment after 16 w, 1 pt was treated for 32 w, and 1 pt progressed after 4 w at 40mg.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961354.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Gamelin E, Mineur L, Chevelle C, Cailleux P, Martin L, Bastit L, Roullet B, Hasbini A, Savary J, Cellier P: Neoadjuvant radiotherapy ± tegafur-uracil plus leucovorin in rectal adenocarcinoma: Final results of a French multicenter phase III study. J Clin Oncol; 2009 May 20;27(15_suppl):4104
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant radiotherapy ± tegafur-uracil plus leucovorin in rectal adenocarcinoma: Final results of a French multicenter phase III study.
  • Primary endpoint was pathological complete response rate (pCR), secondary endpoints included downstaging, QOL, sphincter preservation, recurrence rates, disease-free and overall survival.
  • 172 pts underwent surgery (97.2%), 5 pts were not resected (4 liver and 1 lung metastases plus 1 CVA).
  • With a median follow-up at 22.3 mo, median OS is not yet reached.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961187.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Bible KC, Smallridge RC, Maples WJ, Molina JR, Menefee ME, Suman VJ, Burton JK, Bieber CC, Ivy SP, Erlichman C, Endocrine Malignancies Disease Oriented Group, Mayo Phase 2 Consortium: Phase II trial of pazopanib in progressive, metastatic, iodine-insensitive differentiated thyroid cancers. J Clin Oncol; 2009 May 20;27(15_suppl):3521
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of pazopanib in progressive, metastatic, iodine-insensitive differentiated thyroid cancers.
  • METHODS: A three-outcome one-stage Phase II trial was conducted to assess the anti-tumor activity and toxicities of the orally bioavailable VEGF/tyrosine kinase inhibitor pazopanib (800 mg daily) in patients with advanced and progressive radioiodine-insensitive differentiated thyroid cancers.
  • Common sites of metastases were: lung (100%), nodes (52%), and bone (39%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961328.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Vigo SA, Sansano M, Marmissolle F, Mainella A, Lujan L, Price P, Antonelli M, Mohamed F, Giacomi N: Characteristics and behavior of HER-2/neu positive tumors in patients under 35 years of age with breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e11634
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics and behavior of HER-2/neu positive tumors in patients under 35 years of age with breast cancer.
  • : e11634 Background: Breast cancer (BC) rarely occurs in young women.
  • It is believed that tumor is more aggressive in biologic nature in this group of pts.
  • OBJECTIVE: to describe Her2/neu status, tumor behavior and prognosis in women aged 35 and under with BC.
  • METHODS: We reviewed the records of 45 women aged 35 years or less, with diagnosis of BC between 1999 and 2007.
  • The original Her2 status was analyzed by immunohistochemistry (IHC) with a polyclonal antibody.
  • Stage at diagnosis was I 2 pts and II 6 pts.
  • 5 out of the 8 pts with Her2/neu tumors had axillary node involvement (11.1% out of the total of population), and tumor size was more than 2cm at diagnosis.
  • Disease free survival of 24 month was achieved in 5pts, 1pt died with bone, lung and liver metastases.
  • 2pts had progressive disease (bone and lung metastases one of them, and local recurrence the other one).
  • In this small group of pts lymph node involvement was frequent and tumor size was more than 2cm.
  • Progressive disease with distant metastases in bone, lung and liver was observed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961197.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Gadaleta C, Catino A, Rubini G, Ranieri G, Fazio V, Gadaleta-Caldarola G, Vinciarelli G, Armenise F, Gaudiano A, Mattioli V: Precision pulmonary trans-arterial chemoembolization (PPTACE) plus percutaneous RFA for unresectable lung neoplasms: Initial experience in twelve cases. J Clin Oncol; 2009 May 20;27(15_suppl):7593
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Precision pulmonary trans-arterial chemoembolization (PPTACE) plus percutaneous RFA for unresectable lung neoplasms: Initial experience in twelve cases.
  • : 7593 Background: The study aimed to evaluate the feasibility and safety of precision pulmonary arterial chemoembolization (PPTACE) followed by percutaneous RFA in patients with unresectable lung neoplasms Methods: From November 2007 to October 2008, twelve patients (5 male, 7 female, median age 57) and 20 nodules were treated in 14 sessions.
  • Patients had lung metastases from the following tumors: uterine cancer (2), colorectal carcinoma (7), breast carcinoma (1) and two patients had primary unresectable NSCLC.
  • Both RFA and pulmonary TACE were performed under general anesthesia.
  • After subclavian vein puncture and mapping of arterial vascularization of the segment including the tumoral nodule, antiblastic agents loaded on microspheres (Hepasphere, 50-100 micron in diameter) were selectively perfused in a subsegmental sector.
  • Percutaneous CT-guided RFA of lung nodules was performed 2-7 days after PPTACE.
  • Pretreatment work-up included: contrast-enhanced CT-scan, (18-F)Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (18F-FDG PET/CT) and Ventilation Lung Single Photon Emission Tomography (VL-SPET).
  • Morphological response showed a necrotic area, without contrast-enhancement at CT scan, including the neoplasm plus a large safety zone.
  • VL-SPET showed a wide area without ventilation in lung parenchyma submitted to PPTACE and extending over it; the changes on alveolar ventilation detected by VL- SPET after PPTACE could explain the better heat conduction during RFA.
  • CONCLUSIONS: Lung RFA after pulmonary TACE is feasible and safe.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963406.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Gross ME, Soscia J, Sakowsky S, Castellanos O, Agus DB: Phase I trial of RAD001 (R), bevacizumab (B), and docetaxel (D) for castration-resistant prostate cancer (CRPC). J Clin Oncol; 2009 May 20;27(15_suppl):5154
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of RAD001 (R), bevacizumab (B), and docetaxel (D) for castration-resistant prostate cancer (CRPC).
  • METHODS: Eligible patients (pts) had progressive, metastatic, chemo-naive CRPC.
  • If no DLT occurred after all pts completed 2 cycles in a cohort, pts were enrolled at the next dose level.
  • All pts had PSA elevations, 5 pts had metastasis to lung and/or lymph nodes.
  • 9 pts had bone metastases.
  • DLTs by dose level is summarized as: cohort 1, DLT in 1 of 6 pts (neutropenic fever/grade (Gr) 3, pneumonia/Gr 3, 1 individual pt); cohort 2, DLT in 2 of 2 pts (neutropenic fever /Gr 3, 2 pts); cohort 3, DLT in 3 of 4 pts (neutropenic fever /Gr 3 and Gr 5, pulmonary embolism/ Gr 3, 3 pts).
  • CONCLUSIONS: We conclude that the cohort 1 dose level of D 75 mg/m2, R 2.5 mg, B 15 mg/kg is safe and demonstrates anti-cancer efficacy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964476.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Mel JR Sr, Ramos M, Cueva J, Castellanos J, Almanza C: Pilot study with pegylated liposomal doxorubicin (PLD) and docetaxel as first-line treatment in patients with metastatic breast cancer (MBC). J Clin Oncol; 2009 May 20;27(15_suppl):e12002
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pilot study with pegylated liposomal doxorubicin (PLD) and docetaxel as first-line treatment in patients with metastatic breast cancer (MBC).
  • METHODS: Pts ≥ 18 years with histologically confirmed breast cancer, advanced disease, PS ≥ 60%, LVEF> 50%, adequate bone marrow, renal and hepatic function were included.
  • Pts with brain metastases were excluded.
  • RESULTS: Thirty women with a median age of 64 years (40-81) were included. (76.7%) of pts were postmenopausal, Karnofsky PS 100 and 90 were 48% and 21% respectively, 86% of pts had ductal carcinoma.
  • Most common sites of metastasis were lung (57%), liver (47%), and bone (43%).
  • With a median follow-up of 20.5 months, median time to progression was 8.1 months.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964260.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Calvo A, Ponz-Sarvisé M, Rosell D, Redrado M, Nguewa PA, García-Foncillas J, Abella L, Panizo A, Gil-Bazo I: Use of an inhibitor of differentiation-1 (Id1) expression (exp) to discriminate good prognosis (GP) from poor prognosis (PP) prostate cancer (PCa). J Clin Oncol; 2009 May 20;27(15_suppl):e16128
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of an inhibitor of differentiation-1 (Id1) expression (exp) to discriminate good prognosis (GP) from poor prognosis (PP) prostate cancer (PCa).
  • Id1, involved in cell differentiation and angiogenesis, has recently showed to mediate lung metastasis (mts) from breast cancer.
  • All formalin-fixed and paraffin-embedded primary biopsies and matched mts of 16 of them were stained for tumor and end cell Id1 exp.
  • Among PP, 39% of primary PCa and 38% of mts showed Id1 tumor cell exp and 79% of primary tumors and 81% of mts showed end Id1 exp.
  • In the GP group 0% showed Id1 tumor cell exp, and 50% showed end Id1 exp.
  • The unexpected Id1 exp difference in tumor cells in PP compared to GP pts predicted clinical outcome.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963376.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Flechon A, Pouessel D, Ferlay C, Perol D, Beuzeboc P, Gravis G, Joly F, Oudard S, Deplanque G, Droz J, Culine S: Results of a phase II study of carboplatin and etoposide in patients with progressive metastatic castration refractory prostate cancer (mCRPC) and neuro-endocrine differentiation. J Clin Oncol; 2009 May 20;27(15_suppl):e16073
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of a phase II study of carboplatin and etoposide in patients with progressive metastatic castration refractory prostate cancer (mCRPC) and neuro-endocrine differentiation.
  • We assessed the efficacy and toxicity of a platin-based chemotherapy regimen in patients with mCPRC and neuro-endocrine differentiation defined by: either increased circulating neuro-endocrine markers (chromogranin A: CgA, Neuron Specific Enolase: NSE) more than 1.5 X normal serum values and/or visceral metastases confirmed with immunihistochemical proof of neuro-endocrine differentiation on pathological sample.
  • Patients had bone metastases (78%), lymph nodes involvement (49%), lung metastases (35%), hepatic involvement (33%) and other localizations (17%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963045.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Feldman DR, Sheinfeld J, Bajorin DF, Fischer P, Turkula S, Ishill N, Patil S, Bains M, Bosl GJ, Motzer RJ: Paclitaxel (T) plus ifosfamide (I) followed by high-dose carboplatin (C) and etoposide (E) with autologous stem cell support for patients (pts) with previously treated germ cell tumors (GCT): TI-CE results and prognostic factor analysis in 107 pts. J Clin Oncol; 2009 May 20;27(15_suppl):5027
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 5027 Background: Pts with incomplete response (IR) to first-line chemotherapy or relapsed primary mediastinal non-seminomatous GCT (NSGCT) have <10% 3-year (yr) survival with conventional-dose salvage regimens (Cancer. 67:1305).
  • 5-yr disease-free survival (DFS) was 47% and overall survival 52% with a median follow-up of 61 months (m).
  • On multivariate analysis, primary mediastinal site (p = 0.0002), ≥2 lines of prior therapy (p = 0.0005), baseline HCG >1000 (p = 0.01), and lung metastases (p = 0.02) significantly predicted adverse DFS.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962915.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Cejas P, López-Gómez M, Madero R, De Castro J, Casado E, Belda C, Larrauri J, Barriuso J, González-Barón M, Feliú J: Concordance of K-Ras status between colorectal cancer (CRC) primaries and related metastatic samples considering clinicopathological features. J Clin Oncol; 2009 May 20;27(15_suppl):4053
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concordance of K-Ras status between colorectal cancer (CRC) primaries and related metastatic samples considering clinicopathological features.
  • : 4053 Background: K-Ras mutations in CRC primaries may predict resistance to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies, but we don´t know its behaviour in metastatic tissue.
  • 1) Evaluate the grade of concordance of K-Ras status between primary and related metastatic samples 2) Establish a correlation between k-ras status and individual clinicopathological features Methods: K-ras mutations were retrospectively analysed in primary tumours of 124 patients and 138 related metastatic sites.
  • The primary tumour site was colon in 87 patients and rectum in 37.
  • Sites of metastases were liver (115 samples,83.3%) and lung (23 samples,16.7%).
  • We analyzed K-Ras point mutations in codons 12 and 13 by direct DNA sequencing from paraffin-embedded tumour and studied its relation with 13 clinicopathological features Results: K-Ras mutation was observed in 42(33.6%) primary tumours and in 52(39.1%) related metastatic sites, being the grade of concordance between primary and metastatic sites of 93% (95% CI: 97.5-88.3%).
  • Discordance was observed in 9 (7%) patients: in 2, K-Ras status was wild type in metastatic site and expressed a mutational pattern in the primary tumour; vice versa, in 7, the mutation status was detected in the metastases meanwhile primary tumour was wild type.
  • We also found statistically significative differences in mutation patterns regarding the site of the metastasic tissue: K-ras mutations were detected in 13 lung samples (61.9%) and in 39 liver samples (34.8%) (p=0.028).
  • No other relation with clinicopathological data was detected Conclusions: With this observational analysis, we confirm the high concordance (superior to 90%) between primary and related metastatic sites in terms of K-Ras status; for the first time, we have reported a higher mutational pattern in lung metastases than in liver disease, founds that may have important relevance regarding clinical/treatment decisions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961589.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Al-Niaimi A, Manuelli B, Safdar N, Chappell R, Seo S, Kushner D, Connor J, Hartenbach E: Survival with surgical versus medical treatment of patients with bowel obstruction secondary to ovarian cancer recurrence: A 15-year experience. J Clin Oncol; 2009 May 20;27(15_suppl):e16515
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival with surgical versus medical treatment of patients with bowel obstruction secondary to ovarian cancer recurrence: A 15-year experience.
  • : e16515 Background: To compare the impact of surgical versus medical management on the survival of patients presenting with small bowel obstruction (SBO) secondary to recurrent ovarian cancer.
  • METHODS: The Institutional Review Board approved a retrospective chart review of all patients with SBO due to recurrent ovarian cancer at the University of Wisconsin Hospital between January 1, 1992, and December 31, 2007.
  • The data abstracted from patient charts included demographics, primary cancer characteristics, detailed clinical information at the time of SBO, management strategy, and outcome.
  • RESULTS: 71 patients met our search criteria, 6 were excluded because of a paucity of medical information.
  • 86% of the patients had stage III/IV ovarian cancer, while 14% had stage I/II.
  • The median time from tumor recurrence to bowel obstruction was 17 months.
  • Patients without abdominal or pelvic mass on CT had a median survival of 60 months; patients with any mass noted had a median survival of 3.6 months; patients with liver and lung metastases was 3 months (p = 0.001).
  • CONCLUSIONS: In patients with bowel obstruction due to ovarian cancer recurrence; early stage at diagnosis, the absence of ascites, and lack of abdominal/pelvic mass or distant metastases significantly lengthens survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960754.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Juergens H, Ranft A, Paulussen M, Kontny U, Dilloo D, Dirksen U: Treosulfan-based high-dose chemotherapy with autologous stem cell transplantation in high-risk Ewing sarcoma. J Clin Oncol; 2009 May 20;27(15_suppl):10546
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Seventeen of 21 (81%) PDD-patients had a central axis site of the primary tumor, 8 patients (38%) presented with a pelvic tumor.
  • Metastatic sites were: bone (76%), bone marrow (22%), CNS (10%), liver (15%), lymphnode (29%), other (16%), and additionally lung metastases in 57%.
  • Six of 11 (55%) relapse patients had a late relapse >2 yrs from diagnosis.
  • CONCLUSIONS: Treosulfan-based HDC is an alternative approach in high-risk Ewing tumor patients especially after relapse to consolidate a second remission.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963953.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Mita AC, Sankhala K, Sarantopoulos J, Carmona J, Okuno S, Goel S, Chugh R, Coffey MC, Mettinger K, Mita MM: A phase II study of intravenous (IV) wild-type reovirus (Reolysin) in the treatment of patients with bone and soft tissue sarcomas metastatic to the lung. J Clin Oncol; 2009 May 20;27(15_suppl):10524
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of intravenous (IV) wild-type reovirus (Reolysin) in the treatment of patients with bone and soft tissue sarcomas metastatic to the lung.
  • METHODS: This phase II open-label, single agent study was designed to characterize the efficacy and safety of Reolysin given IV every 28 days in patients (pts) with bone or soft tissue sarcoma with lung metastasis using a Simon two-stage design.
  • 38 pts received prior chemotherapy, radiotherapy, biological agents or combinations for their metastatic disease, 15 pts received more than 3 chemotherapy regimens.
  • Reolysin is well tolerated and shows promise for the treatment of metastatic sarcoma.
  • Primary efficacy goals have been met.
  • Accrual is ongoing to a total of 52 pts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963913.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Simeone E, Daponte A, De Feo G, Montesarchio V, Chiarion-Sileni V, De Michele I, Caracò C, Palmieri G, Mozzillo N, Ascierto PA: Metronomic schedule of temozolomide with conventional dose of cisplatin in metastatic melanoma. J Clin Oncol; 2009 May 20;27(15_suppl):e20009
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metronomic schedule of temozolomide with conventional dose of cisplatin in metastatic melanoma.
  • : e20009 Background: Dacarbazine (DTIC) is the standard treatment for metastatic melanoma.
  • PATIENTS AND METHODS: We reviewed data of metastatic melanoma patients treated at our Institutions with cisplatin (75 mg/m<sup>2</sup> every 28 days) plus TMZ (75 mg/m<sup>2</sup>/die from day 2 for 21 days).
  • Our practice included such scheme for patients younger than 75 years, with a performance status not worse than 2, and adequate bone marrow, liver and renal function.
  • RESULTS: From August 2007 to September 2008, 33 patients were treated with a median age of 44 years (18-74); primary melanoma was ulcerated in 19 cases (58%); most frequent sites of metastases were lung (18 cases), brain and lymph nodes (11 cases each); 29 patients were treated as first-line and 4 as second-line.
  • With a median follow-up of 20 weeks (95% CI: 19-57), there were 19 progressions and a median progression-free survival of 24 weeks (95% CI:16-nr); 9 patients died with a median survival of 50 weeks (95% CI 43-nr).
  • CONCLUSIONS: Results obtained in clinical practice with metronomic temozolomide plus cisplatin in the treatment of patients with metastatic melanoma are encouraging, in light of the negative prognostic features of treated patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962590.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Conte P, Campone M, Pronzato P, Amadori D, Frank R, Schuetz F, Rea D, Wardley A, Britten C, Elias A: Phase I trial of panobinostat (LBH589) in combination with trastuzumab in pretreated HER2-positive metastatic breast cancer (mBC): Preliminary safety and tolerability results. J Clin Oncol; 2009 May 20;27(15_suppl):1081
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of panobinostat (LBH589) in combination with trastuzumab in pretreated HER2-positive metastatic breast cancer (mBC): Preliminary safety and tolerability results.
  • Six pts were ER and PR negative, eight pts had liver metastasis, eight pts had lung metastasis, and two pts had central nervous system metastasis.
  • In the first cohort, two pts experienced tumor reduction of 29% (both had liver metastasis), and four pts received over eight cycles of the combination.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961216.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Yu B, Zhang M, Wu W, Chen L, Peng L, Bian G, Fu J, Fei C: Neoadjuvant chemoradiotherapy for locally advanced low-lying rectal cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15095
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemoradiotherapy for locally advanced low-lying rectal cancer.
  • : e15095 Objective: The aim of this trial was to explore the possibility of further improvement of efficacy in neoadjuvant chemoradiation for the treatment of locally advanced low-lying rectal cancer and the management of patients with clinical complete regression.
  • METHODS: 192 cases with locally advanced low-lying rectal cancer (T3/T4 or N+) received preoperative radiotherapy comprising 40-46 Gy/20-23 fractions and concomitant oral capecitabine 625 mg/m<sup>2</sup> bid for 10 weeks prior to surgery.
  • 17 pts (8.9%) had clinical complete tumor regression without surgery, 175 pts underwent curative resection including of 134 pts with low anterior resection (LAR), 32 pts with ultra-low anterior resection with Parks' coloanal anastomosis and among them 6 pts with diverting temporary colostomy and 9 pts with APR.
  • According to the pathological staging: T<sub>0</sub>N<sub>0</sub> 41 cases, T<sub>2</sub>N<sub>0</sub> 43 cases, T<sub>3</sub>N<sub>0</sub> 77 cases, T<sub>4</sub>N<sub>0</sub> 5 cases, T<sub>2</sub>N<sub>1</sub> 11 cases, T<sub>3</sub>N<sub>1</sub> 13 cases, T<sub>4</sub>N<sub>0</sub> 5 cases, and T<sub>4</sub>N<sub>1</sub> 2 cases; in semiquantitative Dworak's tumor regression grade, TRG0 8 pts,TRG1 32, TRG2 28,TRG3 83 and TRG4 41 with an overall tumor downstaging of 79.2%.
  • During the time, 11 pts had lung metastases, 6 liver metastases and 7 had local recurrences.
  • CONCLUSIONS: Neoadjuvant chemoradiotherapy has high efficacy resulting in tumor down-staging, increased resectability and sphincter preservation, and a reduction in local recurrences.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964612.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Hong S, Rha S, Jeong J, Lee Y, Shin S, Shin K, Roh J: Comparison of long-term outcome between doublet versus triplet neoadjuvant chemotherapy in nonmetastatic osteosarcoma of extremity. J Clin Oncol; 2009 May 20;27(15_suppl):10542
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of long-term outcome between doublet versus triplet neoadjuvant chemotherapy in nonmetastatic osteosarcoma of extremity.
  • : 10542 Background: Multimodal approach had improved outcomes of non-metastatic osteosarcoma.
  • This study was to compare outcomes between doublet (AP; doxorubicin and cisplatin) and triplet (IAP; AP and ifosfamide) neoadjuvant chemotherapy for non-meteastatic osteosarcoma of extremity in a single institute.
  • We assessed tumor response according to pathologic tumor necrosis, and treated further adjuvant chemotherapy.
  • Overall pathologic response was more than 90% tumor necrosis in 74.8% of patients.
  • Total necrosis of tumor was also found in 46 patients (37.4%).
  • Tumor recurrence was occurred in 31.5% of patients with the most common site of lung (84.6%).
  • There was no difference between two groups in recurrence (p=0.17) or lung metastasis (p=0.53).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963960.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Palmerini E, Brach Del Prever A, Fagioli F, Luksch R, Prete A, Tamburini A, Abate ME, Picci P, Ferrari S, Tienghi A: High-dose chemotherapy with autologous stem cell transplantation for relapsed Ewing's sarcoma. J Clin Oncol; 2009 May 20;27(15_suppl):10545
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 10545 Background: Nearly 30-40% of patients with newly diagnosed, non-metastatic Ewing's Sarcoma (EWS) relapse.
  • The role of high-dose chemotherapy (HDCT) with autologous stem cell transplantation (ASCT) is under investigation in metastatic and high risk localized EWS patients.
  • METHODS: All non-metastatic EWS patients treated in Italian Sarcoma Group centers who relapsed between 1999 and June 2008 were offered HDCT (busulfan 4 mg/kg × 4 days orally and melphalan 140 mg/m<sup>2</sup>) with ASCT whenever possible (no previous HDCT; stable or responding disease after standard dose chemotherapy; adequate peripheral blood stem cells harvest).
  • Pattern of relapse was: lung metastases in 20 (28%) patients, bone metastases in 12 (16%), local recurrence in 11 (15%) and multiple sites in 29 (40%).
  • With a median follow-up of 24 months (1-64), the 3-year post-relapse survival (PRS) was 21% (95%CI 7-35).
  • 3-year PRS was better for patients with a lung only relapse [48%, (95%CI 21-74)] and a RFI > 2 years [51%, (95%CI 27-76)].
  • A significant (P 0.02) advantage was observed in the subgroup of patients with a shorter RFI treated with HDCT [3-year PRS 29% (95%CI 5-52)] compared to those treated with standard dose chemotherapy [3-years PRS 13%, (95%CI 2-29)].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963952.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Worden FP, Hooton J, Lee J, Eisbruch A, Wolf GT, Prince M, Moyer J, Teknos T, Chepeha DB, Bradford CR, Carey T: Association of tobacco (T) use with risk of distant metastases (DM), tumor recurrence, and death in patients (pts) with HPV-positive (+) squamous cell cancer of the oropharynx (SCCOP). J Clin Oncol; 2009 May 20;27(15_suppl):6001
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of tobacco (T) use with risk of distant metastases (DM), tumor recurrence, and death in patients (pts) with HPV-positive (+) squamous cell cancer of the oropharynx (SCCOP).
  • : 6001 Background: Chemoradiation (CRT) for HPV (+) SCCOP is associated with a more favorable prognosis than HPV-negative (-) SCCOP.
  • However, the interaction of HPV and T in terms of etiology and disease progression remains unclear.
  • Tumor specimens were analyzed for HPV presence and type.
  • Use of T, determined via self-reporting and chart review, was recorded as both continuous (number of pack-yrs) and categorical (never, former, and current) variables.
  • Former T users were subdivided into an early cessation group (quit ≥ 20 yrs prior to diagnosis) and a late cessation group (quit < 20 yrs prior to diagnosis).
  • Thirty-two HPV (+) pts were never-T users, 88% (28/32) of which remain alive with no evidence of disease; 3 died from other causes and 1 died of lung metastases from SCCOP.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962408.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Feun LG, Levi D, Moon J, Nishida S, Island E, Selvaggi G, Martin P, Savaraj N, Mendes F, Tzakis A: Sorafenib in hepatocellular carcinoma (HCC) patients after liver transplantation. J Clin Oncol; 2009 May 20;27(15_suppl):e15579
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pts at high risk for tumor recurrence (native liver showing vascular invasion, multiple tumors >3 in number, size >6 cm, or lymph node involved) after OLT or who develop recurrence after OLT have worse prognosis.
  • Sorafenib was started 3 months (mo) after OLT as adjuvant therapy (7 pts) or at the time of tumor recurrence after OLT (11 pts).
  • Only 40% could continue at the full recommended starting dose of sorafenib.For the 11 pts with recurrent disease after OLT treated with sorafenib, the sites of evaluable disease include liver (5 pts), lung (3), others (3).
  • One pt (9%) had a partial response in lung metastases for 10 mo. and the median time to tumor progression (TTP) was 4 mo. (range 2-10 mo).
  • For pts on adjuvant sorafenib after OLT, no pt has relapsed so far with a median followup of 6+ mo. (range 2+ to 15+ mo).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962363.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Lu C, Stewart DJ, Ji L, Ramesh R, Jayachandran G, Erasmus J Jr, Lee JJ, Templeton NS, McMannis JD, Roth JA: A phase I trial of intravenous therapy with tumor suppressor FUS1-nanoparticles for recurrent/metastatic lung cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e19065
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I trial of intravenous therapy with tumor suppressor FUS1-nanoparticles for recurrent/metastatic lung cancer.
  • : e19065 Background: The tumor suppressor gene FUS1 is frequently inactivated early in lung cancer development.
  • FUS1 mediates apoptosis in cancer cells but not normal cells through its interaction with Apaf1.
  • DOTAP:cholesterol nanoparticles encapsulating a FUS1 expression plasmid showed selective uptake by cancer cells and activity in mouse xenograft metastatic lung cancer models.
  • METHODS: Patients with recurrent/metastatic lung cancer previously treated with platinum-based chemotherapy were treated with escalating doses of intravenous DOTAP:cholesterol FUS1 nanoparticles.
  • Pre and 24 hour posttreatment tumor biopsies were obtained from 4 patients.
  • CONCLUSIONS: DOTAP:cholesterol FUS1 nanoparticles can be safely administered intravenously in lung cancer patients with demonstrable gene expression in posttreatement tumor biopsies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962142.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Bromley E, Owczarczak B, Keltner L, Wang S, Gollnick SO: Characterization of an antitumor immune response after light-activated drug therapy using talaporfin sodium in a spontaneously metastasizing mammary tumor model. J Clin Oncol; 2009 May 20;27(15_suppl):3052
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of an antitumor immune response after light-activated drug therapy using talaporfin sodium in a spontaneously metastasizing mammary tumor model.
  • Tumor destruction involves direct and indirect tumor kill through apoptosis, vascular occlusion, and potentially antitumor immunologic effects.
  • To provide evidence for the potential antitumor immunologic effects, we have used the therapy to treat primary tumors and examine prevention of metastases in the 4T1 tumor model, an aggressive, spontaneously metastasizing murine mammary tumor model that mirrors human breast cancer.
  • When grown in the mammary fat pad of BALB/c mice, untreated 4T1 tumors rapidly metastasize to lung, liver, lymph nodes, and brain.
  • METHODS: To confirm tumor kill by this therapy, the primary 4T1 tumors grown in mice were treated and animal survival was followed.
  • To determine whether the therapy could enhance antitumor immunity and reduce metastases, the lymph node (LN) cells from treated and control mice were transferred to naïve recipient mice.
  • Recipients were challenged with a tumorigenic dose of 4T1 cells 3 days after adoptive transfer and primary and secondary tumor growth in the recipients was examined.
  • LN cells isolated from treated mice, but not control mice, significantly inhibited primary tumor growth in recipients (p≤0.0001) and dramatically reduced the number of lung metastases present 40d after tumor challenge (p≤0.02).
  • The ability to inhibit primary and secondary tumor growth in recipients depended on the presence of CD8<sup>+</sup> T cells; depletion of CD8<sup>+</sup> T cells from the LN abolished the effect.
  • CONCLUSIONS: These results indicated that this light-activated drug therapy not only destroyed the treated tumors directly but also controlled growth of untreated tumors through induction of a specific host antitumor immune response mediated by CD8<sup>+</sup> T cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962000.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Pariyar J: Gestational trophoblastic disease in Nepalese women managed in B. P. Koirala Memorial Cancer Hospital. J Clin Oncol; 2009 May 20;27(15_suppl):e16570
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gestational trophoblastic disease in Nepalese women managed in B. P. Koirala Memorial Cancer Hospital.
  • Koirala Memorial Cancer Hospital, Nepal from 2001 to 2007 were analyzed.
  • The age of the patients ranged from 16 to 50 years with a mean age of 29.1 years (SD 9.4 years).
  • There were 17 cases (37.8%) of hydatidiform mole, 6 were invasive mole (13.35%), 4 of persistent gestational trophoblastic tumour (8.8%) and 22 patients (48.8%) of choriocarcinoma.
  • Theca Leuteal cyst was present in 11 (24.5%), 17 (37.8%) cases had lung metastasis, 4 (8.9%) had brain metastasis and another 4 (8.9%) had disseminated disease detecteted radiologically.
  • Brain irradiation was required in a case with brain metastasis.
  • CONCLUSIONS: Early diagnosis of disease and proper management strongly influences the outcome of GTD.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961513.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Nieder C, Pawinski A, Haukland E, Dokmo R, Philippi I, Dalhaug A: Estimating the need for palliative external beam radiotherapy in adult cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):e20599
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estimating the need for palliative external beam radiotherapy in adult cancer patients.
  • Newer data accounting for the increasing life expectancy of patients with metastatic cancer are lacking.
  • METHODS: Prospective collection of data on palliative RT in adult cancer patients during a 12 months period in 2007/2008 in a well defined region of Norway.
  • All patients (median age 70 years, 26% lung, 23% prostate, 11% breast, 7% bladder cancer, 33% others) were treated in one federal state with ∼234,000 inhabitants and had unlimited access to RT (no economical barriers, waiting time 0-14 days).
  • RESULTS: In the study population, 134 annual treatments per 100,000 inhabitants were registered (after correction for overuse, but not accounting for emerging treatment options, e.g., stereotactic RT for lung metastases; 95% CI 112-159).
  • In regions with significantly different cancer incidence, age structure and other socioeconomic factors then northern Europe, separate analyses need to be conducted.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961157.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Kennecke HF, Voduc D, Leung S, Cryns VL, Perou CM, Nielsen TO, Cheang M: α-basic-crystallin expression in basal-like breast cancer and its association with brain metastasis. J Clin Oncol; 2009 May 20;27(15_suppl):1025
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] α-basic-crystallin expression in basal-like breast cancer and its association with brain metastasis.
  • : 1025 Background: Basal-like breast cancers are high grade tumors with poor prognosis, having propensity for brain and lung metastasis (Perou et al.
  • Clin Cancer Res 14:1368-76, 2008, Luck et al.
  • Here we investigate the association of αBC with sites of distant metastasis in a large cohort of breast cancer patients.
  • METHODS: Our cohort consists of 4046 early invasive breast cancers referred to the British Columbia Cancer Agency from 1986 to 1992.
  • Breast cancer subtypes were defined using a surrogate of six immunohistochemical markers: ER, PR, HER2, Ki-67, epidermal growth factor receptor and cytokeratin 5/6.
  • All documented sites of distant metastasis were abstracted by chart review according to predefined categories.
  • Among patients who developed distant metastatic disease, the 10-yr BCSS survival in αBC+ and - tumors was 12% and 29%.
  • Sites of metastatic disease included: brain (15%), lung (35%), liver (35%) and bone (65%).
  • Brain metastasis was significantly more common among αBC positive tumors (Fisher's Exact test p<10e-8).
  • Basal-like tumors with brain metastasis commonly co-expressed αBC (Chi-square p=0.006).
  • CONCLUSION: αBC is significantly associated with brain metastasis, particularly among basal breast cancers.
  • These findings suggested that αBC may be involved in tumor cell metastasis and may allow early identification of a subset of patients at particularly high risk of brain metastasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961038.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Li W, Zhang W, Cai S, Yin J, Li J: Prognostic factors for colorectal cancer patients with pulmonary metastases. J Clin Oncol; 2009 May 20;27(15_suppl):e15107
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors for colorectal cancer patients with pulmonary metastases.
  • : e15107 Background: Pulmonary is the second common metastastic site of CRC with a good survival after metastasectomy, however the general situation of pulmonary metastases from CRC has received little attention, especially for unresectable ones.
  • The aim of this study was to determine factors that may influence survival and disease free interval from primary radical surgery to pulmonary metastases (DFI).
  • METHODS: From 01/2000 to 11/2008, a total of 206 pts with pulmonary metastases (colon72, rectal ca131, 3 unknown) were collected retrospectively and the clinical data were analyzed using Kaplan-Meier survival curves, univariate and multivariate analysis.
  • RESULTS: 128 pts (62.1%) had lung disease as the first metastatic site and 33 pts (26.7%) had synchronous liver involvement.
  • Only 17 patients (8.3%) followed pulmonary metastatic resection, and others underwent palliative medical treatment including the chemotherapy and intervention.
  • Median survival was 16.0 months (range 12.240-19.760) with a 18% 5-year survival.
  • Of the totally 160 patients who had synchronous pulmonary metastases after radical primary tumor surgery, the mDFI was 20 months (range 16.738-23.262) months.
  • Rectal cancer had a high chance (65%) for lung recurrence with longer DFI (21 vs 14 mo, P=0.02), but no difference of survival was shown compared to colon cancer.
  • The factors influencing the DFI of metachronous pulmonary metastases included primary tumor site, pathological morphology, tumor infiltration stage and regional lymph node stage (P<0.05).
  • There was a trend of better survival of patients receiving resection surgery after pulmonary metastases than receiving chemotherapy alone though no statistical significant was reached (mOS:34 vs 16 mo, P=0.125).
  • But to patients who receiving metastatic site resection, chemotherapy after surgery improved the survival (P=0.042).
  • The invasive tumor with high stage may have a shorter disease free interval of pulmonary metastases after primary surgery.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964342.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Kojima Y, Ueno H, Okusaka T, Morizane C, Kondo S, Hagihara A, Iwasa S: Hepatocellular carcinoma presenting with lung metastasis: Clinical characteristics and prognostic factors. J Clin Oncol; 2009 May 20;27(15_suppl):e15604
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocellular carcinoma presenting with lung metastasis: Clinical characteristics and prognostic factors.
  • : e15604 Background: The efficacy of systemic chemotherapy for hepatocellular carcinoma (HCC) has been limited, but sorafenib has changed the strategy treating for metastatic HCC.
  • The lung is one of the most common metastatic sites for HCC.
  • Therefore, we focused on clinical features and prognostic factors of HCC patients (pts) with lung metastasis in this study.
  • During this period, extrahepatic metastasis was detected in 286 pts, and the initial metastatic site was lung in 130 pts.
  • The relationships between the characteristics of these pts at the time of lung metastasis detection and prognosis were examined.
  • The Child-Pugh classification was A in 84 pts, B in 32 pts.
  • Univariate analysis revealed 12 of the 20 variables evaluated to be significantly associated with survival time: number of lung metastasis, presence of intrahepatic HCC, maximum size of intrahepatic HCC, presence of tumor thrombus, AFP, PIVKA II, albumin, prothrombin time, ALP, presence of ascites, Child-Pugh classification, and previous history of hepatic resection.
  • Multivariate analysis using the Cox proportional hazards model demonstrated a lower number (≤5) of lung metastases (p<0.0001), the absence of intrahepatic HCC (p=0.0002), and the absence of ascites (p=0.0339) to be independent favorable prognostic factors.
  • CONCLUSIONS: These results may provide useful reference data for determining treatment strategies and planning further clinical trials involving HCC patients with lung metastasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962680.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Karimdjee BS Sr, Cambien MB, Richard MP, Bereder J Sr, Scoazec MJ, Birnbaum MD, Mounier MN, Schmid MH, Schmid MA: Organ-specific inhibition of metastatic colon carcinoma by CXCR3 antagonism. J Clin Oncol; 2009 May 20;27(15_suppl):e14619
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Organ-specific inhibition of metastatic colon carcinoma by CXCR3 antagonism.
  • : e14619 Background: Liver and lung metastases are the predominant cause of colorectal cancer (CRC) related mortality.
  • Recent research has indicated that CXCR3/chemokines interactions that orchestrate hematopoetic cell movement are implicated in the metastatic process of malignant tumors, including that of CRC cells to lymph nodes.
  • To date, however, the contribution of CXCR3 to liver and lung metastasis in CRC has not been addressed.
  • METHODS: To determine whether CXCR3 receptors regulate malignancy-related properties of CRC cells, we have used CXCR3-expressing CRC cell lines of human (HT29 cells) and murine (C26 cells) origins that enable the development of liver and lung metastases when injected into immunodeficient and immunocompetent mice, respectively, and assessed the effect of CXCR3 blockade using AMG487, a small molecular weight antagonist.
  • In vivo, systemic CXCR3 antagonism by preventive or curative treatments with AMG487 markedly inhibited metastasis of human and mouse CRC cells to the lung without affecting that to the liver.
  • Also, we measured increased levels of CXCR3 and ligands expression within lung nodules compared to liver tumors.
  • CONCLUSIONS: Altogether, our findings indicate that CXCR3 is a key mediator for lung metastasis of colon carcinoma and identify CXCR3-blocking approaches as promising strategies against established lung metastases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964128.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Han W, Kim H, Lee J, Lee K, Moon H, Ko E, Kim E, Yu J, Noh D: Value of preoperative staging of breast cancer patients using computed tomography to detect asymptomatic lung and liver metastasis. J Clin Oncol; 2009 May 20;27(15_suppl):1105
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Value of preoperative staging of breast cancer patients using computed tomography to detect asymptomatic lung and liver metastasis.
  • : 1105 Background: Preoperative clinical staging in breast cancer patients is important to determine the most appropriate treatment plans and to predict prognosis for individual patients.
  • Identifying unexpected distant metastases in newly diagnosed breast cancer patients frequently alters initial treatment plans.
  • Routine imaging studies to detect lung or liver metastasis is not indicated in patients with early and operable breast cancer.
  • A recent study showed that routine use of chest radiograph and liver ultrasound does not provide much diagnostic benefit in early breast cancer patients.
  • METHODS: We aimed to investigate the value of preoperative computed tomography to detect asymptomatic liver and lung metastasis in breast cancer patients.
  • We performed preoperative CT for 667 breast cancer patients to detect lung and liver metastasis among 1,636 primary breast cancer patients who had been diagnosed and treated between January 2006 and December 2007 at Seoul National University Hospital.
  • RESULTS: CT showed abnormal findings (suspicious of metastasis or indeterminate nodules) in 78 patients (10.5%).
  • Among these, abnormal finding in 13 patients (1.7%) turned out to be true metastatic lesions.
  • There was no CT-detected lung or liver metastasis in patients with T1 tumor and 4 metastases in patients with T2 tumor.
  • There was no CT-detected lung or liver metastasis in patients with negative axillary lymph node metastasis.
  • When patients were classified according to the AJCC staging, CT-detected true metastatic lesions were only present in stage III patients (13 out of 173 patients, 7.5%).
  • The true metastatic lesions in lung or liver were all small sized nodules, ranging from 0.3cm to 1.2cm in largest diameters.
  • In seven patients, the CT-detected metastatic lesions were less than 1cm which is in contrast with the previous studies.
  • CONCLUSIONS: Our results demonstrated the lack of usefulness in performing routine CT exams to detect asymptomatic liver and lung metastasis in early breast cancer patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962171.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Handkiewicz-Junak D, Roskosz J, Kropinska A, Kozielski J, Krzywiecki A, Krajewska J, Krajewska J, Puch Z, Olczyk T, Jarzab B: Efficacy and safety of radioiodine in the treatment of disseminated differentiated thyroid cancer (DTC) in children. J Clin Oncol; 2009 May 20;27(15_suppl):10065
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and safety of radioiodine in the treatment of disseminated differentiated thyroid cancer (DTC) in children.
  • : 10065 Background: Distant metastases, mainly to lung are diagnosed in about 20% of children with DTC.
  • However, it can results in massive lung fibrosis as was showed in historical groups of patients.The aim of this retrospective study was to evaluate results of radioiodine therapy in children and its long-term safety.
  • METHODS: From 235 children (median age 13.9) diagnosed either with papillary (82%) or follicular cancer (18%), 42 (17.9%) had lung, and 2 (9%) bone metastases (median time of observation 105 months).
  • RESULTS: In most children, 29/44 (66%), distant metastases were diagnosed in radioiodine scan while radiological examinations were normal.
  • In 5/28 (18%) of the children with lung metastases some small foci of focal lung fibrosis were diagnosed with CT.
  • However, comparable percentage of focal fibrosis was observed in DTC children without lung metastases.
  • CONCLUSIONS: Complete remission of distant metastases can be achieved in about 85% of children with DTC treated with radioiodine.
  • This therapy is safe and does not cause any increased risk of lung fibrosis even in children treated with repeated courses of radioiodine.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962500.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Yhim H, Han S, Oh D, Han W, Im S, Kim T, Kim Y, Noh D, Ha S, Bang Y: The prognostic factors for the recurred breast cancer patients with isolated, limited number of lung metastasis, and the implication of pulmonary metastasectomy. J Clin Oncol; 2009 May 20;27(15_suppl):1112
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prognostic factors for the recurred breast cancer patients with isolated, limited number of lung metastasis, and the implication of pulmonary metastasectomy.
  • : 1112 Background: In recurred breast cancer (BC) with isolated lung metastasis, the role of pulmonary metastasectomy (PM) is not established.
  • METHODS: We consecutively enrolled recurred BC patients (pts) with isolated lung metastasis from 1997 to 2007 in Seoul National University Hospital.
  • Among 140 recurred pts with isolated lung metastasis, 45 had metastatic lesions less than 4.
  • The median disease-free interval (DFI, Time from initial BC diagnosis to recur) was 26.1 (range 4.2-168.0) months, and the pts with DFI of less than 24 months were 20 (44%).
  • CONCLUSIONS: In recurred BC with isolated, limited number (less than 4) of lung metastasis, DFI and BS were prognostic factors for PFS and OS.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962208.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Piperno-Neumann S, Homicsko K, Mussot S, Anract P, Laurence V, Pierga J, Mignot L, Chapelier A: A retrospective study of parameters influencing survival after surgical resection of lung metastases of bone and soft tissue sarcomas. J Clin Oncol; 2009 May 20;27(15_suppl):10541
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A retrospective study of parameters influencing survival after surgical resection of lung metastases of bone and soft tissue sarcomas.
  • : 10541 Background: Due to the high rate of isolated lung metastases of sarcomas, a multidisciplinary approach combining chemotherapy with pulmonary metastasectomy (PM) is helpful to achieve R0 resection and try to increase progression free survival (PFS) and overall survival (OS).
  • The aim of this retrospective study is to describe the clinical and tumor features of 70 consecutive operated patients and to identify the factors influencing survival.
  • RESULTS: 64 patients had grade II/III sarcomas of mainly lower limb origin.15 patients had synchronous lung metastases, 35 showed bilateral lesions (mean number of 4, mean size of 12 mm).
  • The primary tumor treatment consisted in conservative surgery in 58 patients (83%).
  • 49 patients received neo and/or adjuvant chemotherapy, 22 patients had postoperative radiotherapy.
  • The resection margins were classified R0/R1/R2 in 54/16/0 patients, R0 was confirmed in 44 by CT scan in a month after PM.
  • With a median FU from diagnosis of 7.7 years, the median OS for all patients reached 59 months, and the median survival after metastasectomy (OSPM) 31 months.
  • 25 patients underwent subsequent PM for recurrent lung metastases, 30 are still alive.
  • On univariate analysis, primary high grade, DFI>24 months, number of metastases>3 and largest diameter>25 mm were significant negative factors for OS.
  • Multivariate analysis confirmed the importance of high grade, DFI, and size of metastases for OS.
  • DFI may be a surrogate marker for tumor biology.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963959.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Gardner K, Judson I, Leahy M, Barquin E, Marotti M, Collins B, Young H, Scurr M: Activity of cediranib, a highly potent and selective VEGF signaling inhibitor, in alveolar soft part sarcoma. J Clin Oncol; 2009 May 20;27(15_suppl):10523
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is typically indolent but with a high incidence of metastatic disease, usually to lungs, but also to sites such as the brain.
  • Response to conventional chemotherapy is poor (overall response rates are approximately 7% [Reichardt P et al,Eur J Cancer.2003;39:1511-1516]).
  • One patient was treated in a phase II randomized trial of cediranib ± prophylactic antihypertensive therapy and six were treated in a Phase II study in patients with imatinib-refractory gastrointestinal stromal tumors or other STS.
  • RESULTS: Median age at diagnosis was 39 years (range: 26-49).
  • All patients had pulmonary metastases and two had additional sites of disease (brain, bone, intra-abdominal) at study entry.
  • Four patients had a best response of partial response, two patients had a confirmed reduction in maximum tumor diameter of ≥10% and <30% and one patient experienced stable disease.
  • As of November 2008, three patients remain on treatment with a median (range) time on study of 61 weeks (49-74).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963912.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Fedyanin M, Tryakin A, Titov D, Zakharova T, Fainstein I, Figurin K, Polockii B, Sergeev J, Garin A, Tjulandin S: Importance of maintenance of dose intensity (DI) during induction chemotherapy (iCT) for metastatic nonseminomatous germ cell tumors (NSGCT). J Clin Oncol; 2009 May 20;27(15_suppl):e16063
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Importance of maintenance of dose intensity (DI) during induction chemotherapy (iCT) for metastatic nonseminomatous germ cell tumors (NSGCT).
  • : e16063 Background: Cisplatin- and etoposide-based CT allows curing the majority of patients (pts) with metastatic germ cell tumor.
  • In the retrospective study we analyzed the role of DI of iCT on metastatic NSGCT.
  • In pts with the intermediate prognosis: DI of etoposide <80% (HR 4.73; 95 % CI 4.85-25.04) and presence of pulmonary metastases (HR 0.45, 95% Cl 0.203-0.977).
  • CONCLUSIONS: Maintaining a DI of greater then 80% of etoposide during iCT, for the treatment metastatic NSGCT, is one of the crucial factors for pts outcome, particularly in intermediate and poor IGCCCG prognostic groups.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963067.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Murata S, Naito H, Yamamoto H, Mekata E, Shimizu T, Shiomi H, Naka S, Abe H, Kurumi Y, Tani T: Phase II trial of adjuvant hyperthermic intraperitoneal chemotherapy with three drugs for the prophylactic treatment of carcinomatosis after resection of advanced gastric cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15588
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of adjuvant hyperthermic intraperitoneal chemotherapy with three drugs for the prophylactic treatment of carcinomatosis after resection of advanced gastric cancer.
  • : e15588 Background: This prospective study was performed to assess the efficacy and safety of hyperthermic intraperitoneal chemotherapy (HIPEC) with three drugs in patients with curative resection of T3 or T4 advanced gastric cancer.
  • METHODS: Patients with curative resection of clinically T3 or T4 advanced gastric cancer were required to be under 75 years of age and to have adequate organ function.
  • After the curative resection of gastric cancer with D2 lymph node dissection and the reconstruction of the alimentary tract, HIPEC was carried out for 30 minutes with 50mg of CDDP, 10mg of MMC, and 1000mg of 5-FU in 5 L saline maintained at 42-43°C.
  • Three patients with pT3 had recurrence of pleural dissemination (n=1), lymph node metastases (n=1), or pulmonary metastases and peritoneal dissemination (n=1).
  • A total of 7 patients had postoperative complications such as continuous pancreatic juice secretion (13.8%), abdominal abscess (10.3%), leakage of the anastomosis (3.4%), and pulmonary insufficiency (10.3%).
  • CONCLUSIONS: The present study suggests that HIPEC with three drugs after curative resection of advanced gastric primary cancer is associated with improved overall survival with an acceptable morbidity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962346.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Kim S, Hwang M, Park Y, Park S, Kim Y, Ryu K, Lee J, Park Y, Kim N, Park S: Prognostic impact of response to second-line chemotherapy on overall survival of patients with advanced gastric cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15551
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic impact of response to second-line chemotherapy on overall survival of patients with advanced gastric cancer.
  • : e15551 Background: It has been debated on whether tumor response to first-line chemotherapy (CT) would be reliable predictor for overall survival (OS) of cancer patients (pts).
  • In case of advanced gastric cancer (AGC), many pts receive 2<sup>nd</sup> line CT after failure to 1<sup>st</sup> line treatment, so response to 2<sup>nd</sup> line CT as well as 1<sup>st</sup> line could affect OS.
  • METHODS: We retrieved clinical data of a total of 1,335 pts with AGC treated with palliative CT from January 2000 to December 2006 in National Cancer Center, Korea, including 757 pts who also received 2<sup>nd</sup> line CT.
  • Retrospective analysis was done to find correlation between objective tumor response to 1<sup>st</sup> and 2<sup>nd</sup> line CT and OS of the 504 pts, whom we divided into 4 groups: responders to both 1<sup>st</sup> and 2<sup>nd</sup> line CT (RR group); responders to 1<sup>st</sup> but not to 2nd line CT (RN group); responders to 2<sup>nd</sup> but not to 1<sup>st</sup> line CT (NR group); and nonresponders to both 1<sup>st</sup> and 2<sup>nd</sup> line CT (NN group).
  • 33/177/29/265 pts were assigned to each of RR/RN/NR/NN group, respectively.
  • Overall survival of RR, RN, NR, and NN group was 31.8 mo, 15.5 mo, 18.9 mo, and 9.2 mo, respectively (p<0.001).
  • Multivariate analysis revealed relapsed disease after curative surgery, well-differentiated histology, absence of pulmonary metastasis, higher serum albumin level, lower serum bilirubin and alkaline phosphatase level, response to both of 1<sup>st</sup> line and 2<sup>nd</sup> line CT were reliable factors for favorable survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962342.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Davies MA, Stemke-Hale K, Calderone T, Deng W, Lazar A, Prieto VG, Aldape K, Mills GB, Gershenwald JE: Quantitative assessment of AKT activation in melanoma. J Clin Oncol; 2009 May 20;27(15_suppl):9022
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Little direct information is known about the activation of the PI3K-AKT signaling pathway in melanoma, particularly in metastases.
  • RESULTS: Samples from 75 regional metastases (LN or in-transit) and 24 distant metastases were analyzed.
  • Technical replicates (same lysate) and biological replicates (same tumor, different lysates) demonstrated average Pearson correlation coefficients (r) of > 0.90, supporting the high technical quality of the analysis.
  • Analysis of distant metastases demonstrated that brain metastases had higher levels of p-AKT, p-GSK3, and p-TSC2, and lower levels of PTEN, compared to metastases to the lung or liver.
  • Activation of the PI3K-AKT pathway may contribute to the aggressiveness of brain metastases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962372.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Tryakin A, Fedyanin M, Bulanov A, Titov D, Allakhverdiyeva G, Mitin A, Sergeev J, Zaharova T, Garin A, Tjulandin S: Prognostic factors in advanced seminoma in the era of etoposide- and cisplatin-based chemotherapy: Importance of pretreatment LDH-level. J Clin Oncol; 2009 May 20;27(15_suppl):e16038
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e16038 Background: The commonly used IGCCCG classification probably underestimates other prognostic factors (tumor markers, stage) for advanced seminoma, which was shown later (Fossa S., 1997).
  • 227 (91%) pts had primary testicular tumor, 241 (96%) pts belonged to IGCCCG good prognostic group.
  • Univariate analysis revealed following factors as significant: number of metastatic sites, presence of pulmonary metastases, RPLN size, hCG level, and LDH level.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962946.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Hoffman RM, Zhao M, Hayashi K: Efficacy of a genetically modified Salmonella typhymurium against metastatic osteosarcoma in an orthotopic mouse model. J Clin Oncol; 2009 May 20;27(15_suppl):10543
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of a genetically modified Salmonella typhymurium against metastatic osteosarcoma in an orthotopic mouse model.
  • : 10543 Background: We have previously developed a genetically-modified strain of S. typhimurium, selected for tumor targeting and therapy in vivo.
  • METHODS: In this study, the tumor-targeting strain of S. typhimurium, termed A1-R, was administered i.v. to nude mice which have primary bone tumor and lung metastasis.
  • Primary bone tumor was obtained by orthotopic intratibial injection of 5 × 10<sup>5</sup>143B-RFP (red fluorescent protein) human osteosarcoma cells.
  • On day 28, lung samples were excised and observed with the Olympus OV100 Small Animal Imaging System.
  • RESULTS: The size of the primary tumor and RFP intensity of lung metastasis were measured.
  • Primary bone tumor size (fluorescence area [mm<sup>2</sup>]) was 232 ± 70 in the untreated group and 95 ± 23 in the treated group (P<0.05).
  • RFP intensity of the lung metastasis was 3 ± 1.5 × 10<sup>6</sup>in the untreated group and 0.42 ± 0.33 × 10<sup>6</sup> in the treated group (P<0.05).
  • CONCLUSIONS: Therefore, bacterial treatment was effective for both primary bone tumor and lung metastasis.
  • Treatment with the tumor-targeting but non-toxic mutant of S. typhimuriumis a promising approach to therapy of metastatic osteosarcoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963961.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Sima L, Yin C: Efficacy of electroacupuncture for bone metastatic cancer patients with neuropathic pain: A randomized controlled trial. J Clin Oncol; 2009 May 20;27(15_suppl):9534
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of electroacupuncture for bone metastatic cancer patients with neuropathic pain: A randomized controlled trial.
  • : 9534 Background: Bone metastatic lung cancer or breast cancer pts often have neuropathic pain which has poor reaction to opioids.
  • A clinical trial is to investigate efficacy of electroacupuncture (EA) in cancer pts with neuropathic pain.
  • METHODS: Inclusion criteria were: bone metastatic lung cancer or breast cancer pts at least one of the symptoms as burning pain, shooting pain, dysesthesias, or allodynia; numerical rating scale (NRS) of pain intensity >=4.0; stable dose of opioids for at least 72 hours.
  • RESULTS: Ninety pts with neuropathic pain participated in a randomized, controlled design trial from 2006 to 2008.
  • Functional Assessment of Cancer Therapy-General (FACT-G) scale had no difference at the beginning, while it were 102±18 and 85±12 in EA group and controlled at the end of survey, p < 0.0001.
  • CONCLUSIONS: EA can alleviate neuropathic pain of bone metastatic cancer pts, decrease the analgesics consumption, and promoting quality of life.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964531.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Sasatomi T, Ogata Y: DWIBS (diffusion weighted whole body imaging with background signal suppression) scan for colorectal cancer and its evaluation: Comparison with CT or PET scans. J Clin Oncol; 2009 May 20;27(15_suppl):e15140
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DWIBS (diffusion weighted whole body imaging with background signal suppression) scan for colorectal cancer and its evaluation: Comparison with CT or PET scans.
  • : e15140 Background: The most important clinical point for the colorectal cancer patients after surgery is to find out local recurrence and distant metastasis to liver or lungs in early state.
  • Recently, DWIBS (diffusion weighted whole body imaging with background body signal suppression) scan, one of the diffusion weighted MRI imaging methods, was developed, and it has been become used for diagnosis of lung cancer and bladder cancer instead of PET scan.
  • In this report, we examined whether it was more useful method for the diagnosis of recurrence or distant metastasis of the colorectal cancer after surgery than PET/CT scan or not.
  • METHODS: All the 12 primary colorectal carcinomas were resected at the surgical division, Kumamoto Central Hospital, Fukuoka Saisekai Ohmuta Hospital and Kurume University Medical Center from 2000 to 2008. (Table 1) After surgery, 14 recurrent regions (seven liver metastasis, two lung metastasis and five local recurrence) were diagnosed by CT and MRI scans.
  • And also the seven out of 12 cases (three liver metastasis, two lung metastasis and four local recurrence) were performed by PET scan.
  • RESULTS: All the 14 metastatic and recurrent regions (seven liver metastasis, two lung metastasis and five local recurrence ) of 12 recurrent patients were performed by DWIBS, MRI and CT scans.
  • Within the seven out of 12 recurrent patients (three liver metastasis, two lung metastasis and five local recurrence), performed by PET scan, all the liver and lung metastatic regions were detected, on the other hand, three out of four local recurrent regions were diagnosed but the other one was not diagnosed by PET scan.
  • CONCLUSIONS: DWIBS is not only useful diagnostic method for local recurrence of colorectal cancer after surgery, but also less invasive method than PET scan.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960889.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Roberge D, Hickeson M, Charest M, Turcotte RE: Utility of total body FDG PET/CT imaging in the initial staging of soft-tissue sarcoma. J Clin Oncol; 2009 May 20;27(15_suppl):10531
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 10531 Background: Soft-tissue sarcoma spreads predominantly to the lung.
  • It is currently unclear how often PET scan will detect metastases not already obvious by chest imaging or clinical examination.
  • RESULTS: From 2004 to 2008, 75 patients met the criteria for this review.
  • In 21% of cases, the primary tumor had been removed by excisional biopsy or unplanned excision prior to staging.
  • The primary tumor was stage T2b in 68% of cases.
  • At the end of staging, 17% of patients were considered to have metastatic disease.
  • Seven of these 64 cases had metastatic disease on chest CT (negative predictive value 89%).
  • 8 PET scans were positive - of these, 4 patients were already known to have metastases, 2 were pathologically proven false positives and 1 was a new finding of a pulmonary metastasis (sensitivity 46%).
  • Three patients had indeterminate PET scans (subsequently none developed metastatic disease).
  • CONCLUSIONS: Although PET scans may be of use in specific circumstances, routine use of FDG PET imaging for detection of metastatic disease as part of the initial staging of soft-tissue sarcoma adds little to chest CT scanning and is unlikely to alter management.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963909.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Nabell LM, Peters G, Meredith R, Carroll W, Bonner J, Ove R, Spencer S: UAB 0210: A phase I/II trial of induction chemotherapy followed by concomitant docetaxel/radiotherapy with subcutaneous amifostine for advanced squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol; 2009 May 20;27(15_suppl):6061
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 3 patients developed isolated pulmonary metastasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961927.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Zhang J, Liao M, Niu X, Xiang J, Zhao Y, Chen H, Lu S: Cross-talking between bone marrow-derived cells and lung cancer cells. J Clin Oncol; 2009 May 20;27(15_suppl):e19068
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cross-talking between bone marrow-derived cells and lung cancer cells.
  • : e19068 Background: Disseminated cancer cells may initially require local nutrients and growth factors to thrive and survive in bone marrow.
  • However, data on the influence of bone marrow derived cells(BMDC, also called bone stromal cells in some publication) on lung cancer cells is largely unexplored.
  • This study is to explore the effect from bone marrow derived cells on biological behavior of lung cancer cells.
  • METHODS: The difference among lung cancer cell lines in their abilities to bone metastasis was tested using SCID animal model.
  • RESULTS: In accordance with other literature repors, H460 was found with high bone metastasis potential, while SPC-A1 and A549 cells were low bone metastasis lung cancer cells.
  • We found bone stromal factors significantly increased the proliferation, invasion, adhesion and expression of angiogenosis-related factors, and inhibited the apoptosis for high bone metastasis H460 lung cancer cells.
  • These biologic effects were not seen in SPC-A1 or A549 cells, which are low bone metastasis lung cancer cells.
  • Ontoexpress software showed main function of 31 genes were associated with signal transduction pathways(5 genes), and adhesion molecule(5 genes), including integrin b3 and ADAMTS-1, two potential targets related with bone metastasis.
  • CONCLUSIONS: We concluded bone marrow derived cells had a profound effect on biological behavior of lung cancers, therefore favoring the growth of lung cancer cells in bone.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962143.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Stephens J, Kaura S, Botteman MF: Cost-effectiveness of zoledronic acid versus placebo in the management of skeletal metastases in lung cancer patients (LC pts): Comparison across three European countries. J Clin Oncol; 2009 May 20;27(15_suppl):8081
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost-effectiveness of zoledronic acid versus placebo in the management of skeletal metastases in lung cancer patients (LC pts): Comparison across three European countries.
  • : 8081 Background: Zoledronic acid (ZOL) reduces the risk of skeletal-related events (SREs) in LC pts with bone metastases.
  • METHODS: Estimated direct costs and quality-adjusted life-years (QALYs) experienced by LC pts with bone metastases receiving placebo (PBO) or ZOL were modeled and compared.
  • Costs of treatments and SREs were estimated using national reimbursement listings (eg, diagnosis-related groups), private databases, and published literature.
  • Use of ZOL resulted in a net increase of 0.017 QALY/pt vs PBO.
  • CONCLUSIONS: ZOL leads to fewer SREs, better estimated QOL, and lower estimated costs relative to PBO in German, French, and UK LC pts with bone metastases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962656.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Gandola L, Nantron M, Marchianò A, Pession A, Indolfi P, Di Cataldo A, Collini P, Arcamone G, Fossati Bellani F, Spreafico F: Outcome in stage IV Wilms tumor treated according to the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) trials. J Clin Oncol; 2009 May 20;27(15_suppl):10031
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome in stage IV Wilms tumor treated according to the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) trials.
  • : 10031 Background: Children with metastases at diagnosis for Wilms tumor (WT) still display a worse prognosis compared to localized disease.
  • Treatment strategy across these trials evolved in terms of sparing whole lung radiotherapy (RT) in case of complete disappearance of lung metastases after primary chemotherapy and a doxorubicin cumulative dose reduction from 360 mg/m<sup>2</sup> to 240 mg/m<sup>2</sup> in TW2003.
  • Adjuvant therapy included 8-month 3-drug chemotherapy for non anaplastic "local" tumor stage I to III (flank RT for stage III), or an intensified regimen for anaplastic histology, adding etoposide, carboplatinum and ifosfamide (6 patients).
  • Overall 19 tumor failure occurred (3 in anaplastic tumors): metastases progression 9, abdominal relapse 5 (combined to liver and mediastinum in 1 case each), lung 4, liver 1.
  • Overall, RFS was 86% in patients who achieved a complete metastases remission (in 2 cases by surgery) compared to 55% in patients who did not (Logrank p<.05).
  • Noteworthy the omission of lung RT in TW2003 trial for complete responders evaluated at week 6 did not jeopardize survival (85% RFS, vs 58% for those children with persistence of metastases and lung RT).
  • There was a trend toward a worse outcome for patients with at least liver metastases (n 13) compared to those with other site (4-yr RFS 49% vs 74%, p=.1).
  • CONCLUSIONS: Failure to obtain metastases complete remission, and maybe site other than lung, should be considered for chemotherapy intensification for metastatic WT.
  • The impact of metastatic tumor burden deserves further analysis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962576.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Penel N, Italiano A, Isambert N, Bompas E, Bousquet G, Bousquet G, Duffaud F: Effect of metastasectomy and doxorubicin dose on the outcome of patients with metastastic leiomyosarcoma: A multicenter study. J Clin Oncol; 2009 May 20;27(15_suppl):10580
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After front-line chemotherapy, 36 patients with lung metastasis (24%) underwent subsequent complete metastasectomy.
  • The univariate analysis identified the following prognostic factors for PFS: performance status (PS), grade, presence of liver or lung metastases.
  • The univariate analysis identified the following prognostic factors: PS, time interval between diagnosis and metastatic relapse, local relapse and grade.
  • Under multivariate analysis, there was only one good prognostic factor for PFS: interval time between initial diagnosis and metastasis > 12 months (p=0.006).
  • CONCLUSIONS: Doxorubicin dose and metastasectomy remain the cornerstone of the optimal treatment of M-LMS.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963870.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Xia J Sr, Zhou J: Antitumor activity of patient-derived renal cell carcinoma cells fused with allogeneic dendritic cells: In vitro results and clinical responses. J Clin Oncol; 2009 May 20;27(15_suppl):3056
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: In the present study, patient-derived tumor cells were fused with allogeneic dendritic cells (DC) to elicit antitumor activity against RCC.
  • RESULTS: After fusion, the created hybrids expressed both tumor-associated antigen and DC-derived molecules and could stimulate the proliferation and IFN-γ secretion of T-cells as well as elicit strong CTL activity against RCC cells in vitro.
  • Percentage of T lymphocyte subsets in peripheral blood of patients was increased significantly.
  • One of 10 patients exhibited a partial response with regression of lung metastases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961996.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Koide N, Kondo H, Suzuki K, Asamura H, Shimada K, Tsuchiya R: Surgical treatment of pulmonary metastasis from hepatocellular carcinoma. Hepatogastroenterology; 2007 Jan-Feb;54(73):152-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of pulmonary metastasis from hepatocellular carcinoma.
  • BACKGROUND/AIMS: The lung is one of the most common sites of extrahepatic spread from hepatocellular carcinoma (HCC).
  • The aim of this study was to evaluate the efficacy of surgical management in patients with pulmonary metastasis from HCC.
  • METHODOLOGY: Fourteen patients with pulmonary metastases arising from HCC underwent surgery at the National Cancer Center Hospital between 1980 and 2001.
  • CONCLUSIONS: Surgical treatment is appropriate option in selected patients for pulmonary metastasis arising from HCC, and might prolong survival.
  • [MeSH-major] Carcinoma, Hepatocellular / secondary. Liver Neoplasms / pathology. Lung Neoplasms / surgery. Pneumonectomy

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. ETHANOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17419251.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 3K9958V90M / Ethanol
  •  go-up   go-down


73. Harrison-Phipps K, Cassivi SD, Nichols FC 3rd, Allen MS, Pairolero PC, Deschamps C: Conventional resection of pulmonary metastases. Multimed Man Cardiothorac Surg; 2007 Jan 1;2007(619):mmcts.2005.001818
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conventional resection of pulmonary metastases.
  • We present an overview of surgical technique for the resection of secondary tumor metastases to the lungs.
  • Issues addressed include the optimal surgical approach, the requirement to remove all lesions while preserving unaffected lung parenchyma and the advantages of the available surgical staplers and devices.
  • In selected patients, resection of metastatic lesions to the lung or chest wall offers a survival benefit.
  • Although pulmonary metastases without further tumor spread may represent unique host or tumor biology, approximately 40% of patients survive 5 years.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24414320.001).
  • [Journal-full-title] Multimedia manual of cardiothoracic surgery : MMCTS
  • [ISO-abbreviation] Multimed Man Cardiothorac Surg
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


74. Etienne-Mastroianni B, Girard N, Ginguene C, Tronc F, Vasiljevic A, Vallee B, Cordier JF: [Pulmonary metastases from malignant meningioma]. Rev Mal Respir; 2010 Sep;27(7):764-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pulmonary metastases from malignant meningioma].
  • [Transliterated title] Métastases pulmonaires de méningiome malin.
  • INTRODUCTION: Pulmonary metastases from meningioma are rare and present with specific clinical and radiological features.
  • The diagnostic and therapeutic management of metastatic meningioma illustrate the concept of orphan thoracic oncology.
  • CASE REPORT: We report the case of a 58-year-old male, former smoker, with a previous history of atypical meningioma and resected lung adenocarcinoma.
  • During oncologic surveillance, a computed-tomography scan disclosed multiple well-defined homogeneous nodules in the right lung.
  • Pathological examination of metastasectomy specimens revealed metastatic malignant meningioma.
  • CONCLUSIONS: Pulmonary metastases may occur in malignant meningioma.
  • [MeSH-major] Lung Neoplasms / secondary. Meningeal Neoplasms / pathology. Meningioma / secondary

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 SPLF. Published by Elsevier Masson SAS. All rights reserved.
  • (PMID = 20863979.001).
  • [ISSN] 1776-2588
  • [Journal-full-title] Revue des maladies respiratoires
  • [ISO-abbreviation] Rev Mal Respir
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


76. Erhunmwunsee L, D'Amico TA: Surgical management of pulmonary metastases. Ann Thorac Surg; 2009 Dec;88(6):2052-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical management of pulmonary metastases.
  • Metastasectomy is the only curative option for some patients with secondary pulmonary malignancy.
  • Many studies suggest a survival benefit in selected patients if complete resection of pulmonary metastases is accomplished.
  • Evaluation for resection must include ascertainment of control of the primary tumor and assessment of the ability to achieve complete resection.
  • [MeSH-major] Colorectal Neoplasms / pathology. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Pneumonectomy / methods

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19932302.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 54
  •  go-up   go-down


77. Liang WC, Guo RP, Chen MS, Long H, Shi M, Wei W, Zhang YQ: [Efficacy of pulmonary resection for primary hepatocellular carcinoma patients with pulmonary metastasis]. Ai Zheng; 2008 Mar;27(3):319-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of pulmonary resection for primary hepatocellular carcinoma patients with pulmonary metastasis].
  • BACKGROUND & OBJECTIVE: Pulmonary resection is considered as an active therapy for malignant tumor patients with pulmonary metastasis.
  • This study was to evaluate the efficacy of pulmonary resection for primary hepatocellular carcinoma (HCC) patients with pulmonary metastasis.
  • METHODS: Clinicpathologic data and outcomes of 12 HCC patients underwent pulmonary resection due to pulmonary metastasis were analyzed.
  • RESULTS: Among the 12 patients, 9 had 1 or 2 pulmonary metastases, 1 of which had relapsed pulmonary metastasis after the first pulmonary resection; the other 3 patients who had 3 or more pulmonary metastases all recurred with pulmonary metastasis after the first pulmonary resection.
  • The median survival time was 52 months after the first hepatectomy and 24 months after the first pulmonary resection.
  • The overall 1-, 3-and 5-year survival rates were 100.0%,75.0% and 47.3% after the first hepatectomy, and 83.3%, 46.7% and 21.0% after the first pulmonary resection, respectively.
  • CONCLUSION: When intrahepatic recurrence is effectively controlled, HCC patients with 1 or 2 pulmonary metastases might benefit from pulmonary resection and achieve prolonged survival.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Pneumonectomy

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18334126.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


78. Chen F, Fujinaga T, Sato K, Sonobe M, Shoji T, Sakai H, Miyahara R, Bando T, Okubo K, Hirata T, Date H: Significance of tumor recurrence before pulmonary metastasis in pulmonary metastasectomy for soft tissue sarcoma. Eur J Surg Oncol; 2009 Jun;35(6):660-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of tumor recurrence before pulmonary metastasis in pulmonary metastasectomy for soft tissue sarcoma.
  • BACKGROUND: Resection for pulmonary metastasis from soft tissue sarcomas is an accepted method for treatment, but it is still debatable which patients will benefit from surgical intervention.
  • To find an entity of patients benefiting from pulmonary metastasectomy, we reviewed our institutional experience.
  • METHODS: Between 1990 and 2007, 23 patients with pulmonary metastases from soft tissue sarcomas underwent complete pulmonary resection.
  • Various perioperative variables were investigated retrospectively to confirm the role of pulmonary metastasectomy and to identify possible prognostic factors for survival after metastasectomy.
  • Disease-free survival rate was 9% at 1 year after pulmonary resection.
  • On multivariate analysis, no tumor recurrence (neither locoregional recurrence nor extrapulmonary metastasis) before pulmonary metastasis provided a significantly favorable overall survival (P=0.038).
  • In addition, repeat metastasectomy for recurrent pulmonary metastasis also provided a favorable overall survival (P=0.041).
  • CONCLUSIONS: Our data suggested that patients most likely to benefit from pulmonary metastasectomy for soft tissue sarcoma have no tumor recurrence before pulmonary metastasis.
  • Furthermore, patients with repeat metastasectomy for recurrent pulmonary metastasis also presented a significantly longer survival.
  • [MeSH-major] Lung Neoplasms / surgery. Neoplasm Recurrence, Local / mortality. Pneumonectomy / mortality. Sarcoma / surgery

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18774675.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


79. Warwick R, Page R: Resection of pulmonary metastases from colorectal carcinoma. Eur J Surg Oncol; 2007 Dec;33 Suppl 2:S59-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resection of pulmonary metastases from colorectal carcinoma.
  • Although pulmonary metastases from colorectal carcinoma (CRC) often represent systemic and uncontrolled tumour growth, in a number of patients lung disease is limited and the patient remains well.
  • When the metastases can be removed, long term survival is a possibility, with 5- and 10-year survivals in the order of 44% and 25%.
  • Pulmonary metastases which are suitable for resection are usually detected on chest radiography, especially when carried out during monitoring of patients.
  • They are rarely a cause of symptoms and the majority of patients have otherwise healthy lungs.
  • CT scans supplemented by PET scans usually confirm the diagnosis, but percutaneous biopsy is sometimes necessary to exclude a primary lung cancer.
  • The criteria for resecting CRC pulmonary metastases are (1) the primary tumour is controlled or is controllable;.
  • (2) complete resection is possible; and (3) the patient has adequate pulmonary reserve to tolerate the planned resection.
  • The majority of patients having resection of pulmonary metastases from CRC recover well with very few post-operative complications.
  • Following resection favourable prognostic factors include a long disease-free interval, small number and small size of metastases, a normal carcinoembryonic antigen level, and an absence of concomitant liver metastases and mediastinal lymph node spread.
  • Surgery for pulmonary metastases of CRC remains the best means of local control and the best way to render the patient disease-free.
  • Patients with complete resection of pulmonary metastases have an improved long-term survival when compared to patients with unresected metastases.
  • [MeSH-major] Colorectal Neoplasms / therapy. Lung Neoplasms / surgery. Pneumonectomy / methods
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Humans. Neoplasm Recurrence, Local / surgery. Patient Selection. Survival Analysis. Thoracic Surgery, Video-Assisted. Thoracotomy

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18023132.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 37
  •  go-up   go-down


80. Bluoss C: [Minimally invasive surgical techniques for the treatment of pulmonary metastases]. Chirurgia (Bucur); 2010 Jan-Feb;105(1):53-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Minimally invasive surgical techniques for the treatment of pulmonary metastases].
  • OBJECTIVE: Raising surgeons' awareness and sensitivity about the use of minimally invasive surgical techniques for the treatment of patients with pulmonary metastases.
  • PATIENTS AND METHODS: The study was based on the data collected from 10 consecutive patients who underwent surgery for lung metastases in our department between 2003 and 2008.
  • RESULTS: The most frequently encountered metastases to the lung were from breast and lung carcinoma; the disease free interval was between 6 months and 20 years.
  • Solitary metastases were the most commonly found ones in imagistic studies.
  • CONCLUSIONS: The advantages of minimally invasive surgical techniques are: shorter hospital stay with lower hospital expenses as well as improving the quality of life of patients with pulmonary metastases.
  • [MeSH-major] Breast Neoplasms / surgery. Carcinoma / surgery. Laparoscopy. Lung Neoplasms / surgery. Pneumonectomy / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Length of Stay. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Quality of Life. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20405680.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


81. Nishimoto J, Amoh Y, Niiyama S, Takasu H, Katsuoka K: Aggressive digital papillary adenocarcinoma on the palm with pulmonary metastases. J Dermatol; 2008 Jul;35(7):468-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive digital papillary adenocarcinoma on the palm with pulmonary metastases.
  • A 41-year-old Japanese male had aggressive digital papillary adenocarcinoma with pulmonary metastases.
  • The tumor consisted of multiple lobules of anaplastic epithelial cells with central necrosis.
  • Two years after the lesion was removed, pulmonary nodular lesions were found on chest X-ray.
  • On histopathological examination, the pulmonary biopsy specimens showed lobular proliferation of acantholytic tumor cells and some ductal structures associated with papillary projections.
  • Five years after the initial removal of the lesion, the patient was referred to our hospital because of a recurrent skin nodule on his left palm.
  • The recurrent skin tumor was found to have lobular proliferation of anaplastic cells.
  • On immunohistochemistry, the pulmonary metastasis and the palmar skin nodules were identical.
  • The tumor was diagnosed as an aggressive digital papillary adenocarcinoma.
  • This report is a rare case of aggressive digital papillary adenocarcinoma that was diagnosed based on the histopathology of the pulmonary metastases, which showed ductal structures associated with papillary projections.
  • [MeSH-major] Adenocarcinoma, Papillary / secondary. Lung Neoplasms / secondary. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18705837.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


82. Kawamura M, Nakajima J, Matsuguma H, Horio H, Miyoshi S, Nakagawa K, Fujisawa T, Kobayashi K, Metastatic Lung Tumor Study Group of Japan: Surgical outcomes for pulmonary metastases from hepatocellular carcinoma. Eur J Cardiothorac Surg; 2008 Jul;34(1):196-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical outcomes for pulmonary metastases from hepatocellular carcinoma.
  • BACKGROUND: Although favourable prognosis following aggressive treatment of extrahepatic metastases from hepatocellular carcinoma (HCC) has been reported, surgical outcomes for pulmonary metastases are unclear.
  • METHODS AND MATERIALS: Sixty-one patients (2.6%) of 2297 registered with the Metastatic Lung Tumor Study Group of Japan between 1990 and 2006, who underwent surgery for pulmonary metastases from HCC, were retrospectively reviewed from the registry.
  • A stepwise regression analysis showed three or less pulmonary metastases to be an independent factor for better prognosis (p=0.048).
  • CONCLUSION: With careful patient selection, comparatively good outcomes can be expected following surgical resection of pulmonary HCC metastases.
  • Among them, patients with multiple metastases, if number of metastases is small such as four or less, can be expected to survive long after surgery.
  • [MeSH-major] Carcinoma, Hepatocellular / secondary. Carcinoma, Hepatocellular / surgery. Liver Neoplasms. Lung Neoplasms / secondary. Lung Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18455409.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


83. Gutiérrez V, Cobo M, Olea D, García J, Ramírez C, Bautista D, Alcalde J: Glucagonoma with two pancreatic masses and pulmonary metastases as debut of MEN-1. Clin Transl Oncol; 2007 Oct;9(10):674-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glucagonoma with two pancreatic masses and pulmonary metastases as debut of MEN-1.
  • This is a rare case of a patient with type 1 multiple endocrine neoplasia (MEN-1) syndrome.
  • The case is further unusual in that the glucagonoma debuted with two synchronic pancreatic masses at the time of diagnosis and with pulmonary metastases as the primary site of metastasis and not the more usual site of the liver.
  • [MeSH-major] Glucagonoma / radionuclide imaging. Lung Neoplasms / radionuclide imaging. Multiple Endocrine Neoplasia Type 1 / radionuclide imaging. Pancreatic Neoplasms / radionuclide imaging

  • Genetic Alliance. consumer health - Glucagonoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17974529.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


84. Iagaru A, Chawla S, Menendez L, Conti PS: 18F-FDG PET and PET/CT for detection of pulmonary metastases from musculoskeletal sarcomas. Nucl Med Commun; 2006 Oct;27(10):795-802
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 18F-FDG PET and PET/CT for detection of pulmonary metastases from musculoskeletal sarcomas.
  • OBJECTIVE: Sarcomas represent a significant therapeutic challenge and their potential for distant pulmonary metastases is well known.
  • However, PET appears to be less accurate in detection of pulmonary metastases.
  • METHODS: This is a retrospective study (January 1995 to December 2004) of 106 patients with histological diagnosis of OSTS, who had PET and PET/CT at our institution.
  • Pulmonary metastases were seen in 40 patients.
  • CONCLUSIONS: Chest CT is more sensitive than PET in detecting pulmonary metastases from OSTS.
  • A significant portion of known pulmonary metastases greater than 1.0 cm on CT, are PET negative.
  • A negative PET scan in the presence of suspicious CT findings in the chest cannot reliably exclude pulmonary metastases from OSTS.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Female. Humans. Lung Neoplasms / diagnosis. Lung Neoplasms / pathology. Male. Middle Aged. Neoplasm Metastasis. Radiography, Thoracic / methods. Retrospective Studies

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16969262.001).
  • [ISSN] 0143-3636
  • [Journal-full-title] Nuclear medicine communications
  • [ISO-abbreviation] Nucl Med Commun
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


85. Suemitsu R, Takeo S, Uesugi N, Inoue Y, Hamatake M, Ichiki M: A long-term survivor with late-onset-repeated pulmonary metastasis of a PEComa. Ann Thorac Cardiovasc Surg; 2010 Dec;16(6):429-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A long-term survivor with late-onset-repeated pulmonary metastasis of a PEComa.
  • A 59-year-old male underwent a surgical resection of a retroperitoneum tumor in 1990 that was diagnosed as leiomyoblastoma.
  • Thereafter he demonstrated pulmonary metastases followed by a total of 3 pulmonary resections from 1995 to 1997.
  • In 2008, he was incidentally found to have a tumor in the left lower lobe, which was diagnosed as a metastatic perivascular epithelioid cell (PEComa) neoplasm.
  • Retrospectively, a primary tumor and pulmonary metastases were also diagnosed as PEComa.
  • We experienced late-onset repeated pulmonary metastasis of a PEComa.
  • [MeSH-major] Perivascular Epithelioid Cell Neoplasms / secondary. Retroperitoneal Neoplasms / pathology
  • [MeSH-minor] Humans. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Male. Middle Aged. Retrospective Studies. Survivors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21263425.001).
  • [ISSN] 2186-1005
  • [Journal-full-title] Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia
  • [ISO-abbreviation] Ann Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


86. Wu PK, Chen WM, Chen CF, Lee OK, Haung CK, Chen TH: Primary osteogenic sarcoma with pulmonary metastasis: clinical results and prognostic factors in 91 patients. Jpn J Clin Oncol; 2009 Aug;39(8):514-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary osteogenic sarcoma with pulmonary metastasis: clinical results and prognostic factors in 91 patients.
  • OBJECTIVE: Osteosarcoma is the most common primary malignant bone tumor.
  • The long-term outcome is poor for patients with metastatic disease.
  • Patients were divided into three groups depending on the time of identification of pulmonary metastasis: group A, identified with primary tumor diagnosis; group B, during whole treatment course; and group C, after completion of treatment.
  • Long-term survival was calculated and factors related to metastases were analyzed.
  • RESULTS: Ninety-one patients developed pulmonary metastases; 21 in group A, 18 in group B and 52 in group C.
  • The mean period from initial diagnosis to lung metastases in groups B and C was 22.2 months (+/-20.6).
  • Five-year survival rates were 82.0% and 38.3% in the non-metastasis group and metastasis group, respectively (P < 0.001).
  • The 5-year survival rate was significantly worse in group A than in group B or C (0%, 7.4%, 59.5%, P < 0.001), in patient with more than one lobe involved (27.0%, P = 0.006) and more than three pulmonary nodule metastases (21.3%, P = 0.002).
  • Factors related to the pulmonary metastasis were: old age (65.5% in older than 27.5 years old and 41.6% in younger, P = 0.017), large tumor volume (54.4% in larger than 202.5 ml and 33.7% in smaller, P = 0.005) and elevated lactodehydrogenase (LDH; 55.1% vs.31.0% in normal, P = 0.001).
  • CONCLUSIONS: The prognosis of osteosarcoma with pulmonary metastases is dismal, especially for patients who have primary pulmonary metastases, more than three pulmonary metastatic nodules or involvement of more than one lobe.
  • Factors such as older age, larger tumor volume and elevated LDH may reflect high metastatic rate.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / pathology. Lung Neoplasms / secondary. Osteosarcoma / secondary. Pneumonectomy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Prognosis. Survival Rate. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Jpn J Clin Oncol. 2010 Jan;40(1):94-5 [19914945.001]
  • (PMID = 19525290.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


87. Ozkoc G, Gonlusen G, Ozalay M, Kayaselcuk F, Pourbagher A, Tandogan RN: Giant chondroblastoma of the scapula with pulmonary metastases. Skeletal Radiol; 2006 Jan;35(1):42-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant chondroblastoma of the scapula with pulmonary metastases.
  • A 53-year-old man presented with a 12-year history of a progressively growing solid mass at his left shoulder.
  • During the 36-month follow-up, he had multiple inoperable metastatic lesions in his lungs.
  • Histology of the transthoracic needle biopsy showed the metastatic nodules had features specific for chondroblastoma; however, the microscopic features additionally had hyperchromasia and increased mitotic activity in some areas.
  • It is exceptional to see this lesion in the sixth decade of life and with pulmonary metastases.
  • [MeSH-major] Bone Neoplasms / diagnosis. Chondroblastoma / diagnosis. Chondroblastoma / secondary. Lung Neoplasms / diagnosis. Lung Neoplasms / secondary. Scapula / pathology. Scapula / radiography

  • Genetic Alliance. consumer health - Chondroblastoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Skeletal Radiol. 2006 Feb;35(2):126
  • (PMID = 16007463.001).
  • [ISSN] 0364-2348
  • [Journal-full-title] Skeletal radiology
  • [ISO-abbreviation] Skeletal Radiol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


88. Xu-Dong S, Zan S, Shui-er Z, Li-na T, Wen-xi Y, Feng L, Yang Y: Expression of Ezrin correlates with lung metastasis in Chinese patients with osteosarcoma. Clin Invest Med; 2009;32(2):E180-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Ezrin correlates with lung metastasis in Chinese patients with osteosarcoma.
  • The analysis of relationships between pulmonary metastasis and overall survival time were carried out based on the clinical data.
  • In addition, we demonstrated that the high mRNA level of Ezrin gene was related to shorter lung metastasis-free and overall survival time of the Chinese patients with osteosarcoma (P < 0.001).
  • CONCLUSION: Our data suggest that Ezrin, but not CD44 and Six1, could be a prognostic factor and a predictor of potential lung metastasis in osteosarcoma.
  • [MeSH-major] Cytoskeletal Proteins / genetics. Cytoskeletal Proteins / metabolism. Lung Neoplasms / metabolism. Lung Neoplasms / secondary. Osteosarcoma / metabolism. Osteosarcoma / pathology


89. Mizushina Y, Bando M, Hosono T, Ohno S, Sohara Y, Hironaka M, Yukihiko S: [Case of pneumothorax due to pulmonary metastases from uterine leiomyosarcoma]. Nihon Kokyuki Gakkai Zasshi; 2008 May;46(5):379-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case of pneumothorax due to pulmonary metastases from uterine leiomyosarcoma].
  • After admission video-assisted thoracoscopic surgery (VATS) showed the pulmonary lesions to be primarily leiomyoma, however, further examination revealed that her uterine sarcoma resected in 2000 exhibited not only mitosis but also venous invasion.
  • We therefore considered her lung tumors as metastases from uterine leiomyosarcoma.
  • Cases of secondary spontaneous pneumothorax (SSP) due to pulmonary metastases are rare and almost half are from mesenchymal tumors.
  • Thin-wall cavities and cysts are formed by a check-valve mechanism in the process of pulmonary metastases formation.
  • When multiple thin-wall cavities and cysts are found in the lung, pulmonary metastases should be considered as one of the causes, and pathological specimens obtained in past illness should be re-examined in detail.
  • [MeSH-major] Leiomyosarcoma / secondary. Lung Neoplasms / secondary. Pneumothorax / etiology. Uterine Neoplasms / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Diagnosis, Differential. Female. Humans. Pneumonectomy. Thoracic Surgery, Video-Assisted. Tomography, X-Ray Computed


90. Yedibela S, Klein P, Feuchter K, Hoffmann M, Meyer T, Papadopoulos T, Göhl J, Hohenberger W: Surgical management of pulmonary metastases from colorectal cancer in 153 patients. Ann Surg Oncol; 2006 Nov;13(11):1538-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical management of pulmonary metastases from colorectal cancer in 153 patients.
  • BACKGROUND: Surgery has become a recognized therapeutic means in selected patients with pulmonary metastases from colorectal origin.
  • We reviewed our experience in the surgical treatment of 153 patients with pulmonary colorectal metastases and investigated factors affecting survival.
  • METHODS: A retrospective analysis of the records of all patients (n = 153) with pulmonary metastases from colorectal cancer who underwent thoracotomy between 1978 and 2003 at a single surgical center was performed.
  • RESULTS: One hundred fifty-three patients with pulmonary metastases from colon (n = 61) or rectal (n = 92) cancer underwent 180 thoracotomies.
  • Sex, age, site, International Union Against Cancer stage of the primary tumor, prethoracotomy carcinoembryonic antigen level, size of metastases, and previous resection of hepatic metastases were not found to be statistically significant prognostic factors.
  • Number of metastases (solitary vs. multiple), mode of operation (wedge vs. anatomical resection), disease-free interval (DFI; > 36 months), negative hilar or mediastinal lymph node status, resection margin > 10 mm, and administration of intraoperative blood substitution were predictors of a longer survival duration by univariate analysis, but only number of metastases (P = .019), mode of operation (P = .004), DFI (P = .027), and intraoperative blood substitution (P = .002) were identified as independent prognostic factors by multivariate analysis.
  • CONCLUSIONS: Pulmonary resection for metastases from colorectal cancer is safe and results in long-term survival in selected patients.
  • Single metastases, anatomical resection, intraoperative blood substitution, and DFI > 36 months seem to be the most reliable predictors of survival.
  • [MeSH-major] Colorectal Neoplasms / surgery. Lung Neoplasms / secondary. Lung Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoembryonic Antigen / metabolism. Female. Humans. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Lymph Node Excision. Lymphatic Metastasis. Male. Medical Records. Middle Aged. Retrospective Studies. Survival Rate. Thoracotomy

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17009154.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  •  go-up   go-down


91. Angelelli G, Grimaldi V, Spinelli F, Scardapane A, Sardaro A: Multi slice computed tomography in the study of pulmonary metastases. Radiol Med; 2008 Oct;113(7):954-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multi slice computed tomography in the study of pulmonary metastases.
  • PURPOSE: This study was undertaken to assess the performance of 16-slice computed tomography (MSCT) using Multi-Planar Reformatting (MPR), Maximum Intensity Projection (MIP) and Volume Rendering (VR) reconstructions to study pulmonary metastases.
  • MATERIALS AND METHODS: CT studies of 32 patients with pulmonary metastases were retrospectively reviewed.
  • For metastasis <or= 5 mm, sensitivity was 22% for 2D images, 87%-89% for MIP and 55%-58% for VR reconstructions.
  • CONCLUSIONS: MIP are the most sensitive reconstructions for detecting small pulmonary nodules.
  • [MeSH-major] Lung Neoplasms / radiography. Lung Neoplasms / secondary. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Data Interpretation, Statistical. Female. Humans. Image Processing, Computer-Assisted. Male. Middle Aged. Observer Variation. Patient Selection. Retrospective Studies. Sensitivity and Specificity. Solitary Pulmonary Nodule / radiography

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18779932.001).
  • [ISSN] 0033-8362
  • [Journal-full-title] La Radiologia medica
  • [ISO-abbreviation] Radiol Med
  • [Language] eng; ita
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


92. Jiang GM, Zhao JW, Chen YX, Tian F: [Blood supply of pulmonary metastases and its clinical significance]. Ai Zheng; 2006 Jul;25(7):885-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Blood supply of pulmonary metastases and its clinical significance].
  • BACKGROUND & OBJECTIVE: Interventional treatment has been widely applied to primary lung carcinoma, but seldom applied to pulmonary metastases because the blood supply of pulmonary metastases has rarely been investigated, and the present understanding is controversial.
  • This study was to explore the correlation of the clinical value of bronchial arterial chemotherapeutic infusion (BAI) combined bronchial arterial embolization (BAE) to the blood supply of pulmonary metastases.
  • METHODS: Bronchial artery angiography was performed on 33 patients with pulmonary metastases to assess the blood supply and the distribution of pulmonary metastases.
  • RESULTS: Of the 89 metastatic nodules in the lungs of 33 patients, 63 (70.8%) were located in the mid-medial zone, and 26 (29.3%) in the lateral region of the lung; 56 had abundant blood supply, and 33 had poor blood supply.
  • The blood supply of pulmonary metastases was correlated to the location of metastatic nodules.
  • The blood supply of bronchial artery had no correlation to the volume of metastatic nodule (P>0.05).
  • Most pulmonary metastases of hepatic cancer were hypervascular and the lipiodol deposited well in the nodules; during the follow-up, the nodules shrunk significantly and kept stable.
  • CONCLUSIONS: Bronchial artery is the major feeding artery of pulmonary metastases.
  • BAI and BAE are effective in treating pulmonary metastases with abundant blood supply.
  • [MeSH-major] Bronchial Arteries / radiography. Chemoembolization, Therapeutic / methods. Lung Neoplasms / blood supply

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16831283.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 0 / hydroxycamptothecinum; 3Z8479ZZ5X / Epirubicin; 8001-40-9 / Iodized Oil; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


93. Bruzzi JF, Truong MT, Gladish GW, Wallace MJ, Moran CA, Munden RF: Development of pulmonary arteriovenous communications within pulmonary metastases after chemotherapy. J Thorac Oncol; 2007 Mar;2(3):243-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of pulmonary arteriovenous communications within pulmonary metastases after chemotherapy.
  • The development of acquired pulmonary arteriovenous communications within pulmonary metastases from an extrathoracic malignancy is a rare phenomenon, but it has potentially serious clinical consequences for the patient.
  • We describe two such patients, both of whom developed intrametastatic pulmonary arteriovenous communications after chemotherapy of the pulmonary metastases, and one of whom required coil embolization for control of symptoms related to the right-to-left shunt.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Arteriovenous Fistula / etiology. Lung Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17410048.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


94. Pennathur A, Abbas G, Qureshi I, Schuchert MJ, Wang Y, Gilbert S, Landreneau RJ, Luketich JD: Radiofrequency ablation for the treatment of pulmonary metastases. Ann Thorac Surg; 2009 Apr;87(4):1030-6; discussion 1036-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiofrequency ablation for the treatment of pulmonary metastases.
  • OBJECTIVES: Surgical resection is the preferred treatment in selected patients with pulmonary metastases.
  • RFA may be used alone or combined with surgical resection as a lung parenchymal-sparing approach.
  • Our objectives were to evaluate the intermediate term outcomes after RFA and to determine the prognostic variables associated with outcome in patients with pulmonary metastases.
  • The primary cancer was colorectal in 9 (41%), renal in 2 (9%), sarcoma in 4 (18%), and other in 7 (32%).
  • CONCLUSIONS: RFA is safe in this group of pulmonary metastases patients, with reasonable results.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Surg. 2000 Aug;191(2):184-90; discussion 190-1 [10945362.001]
  • [Cites] Ann Thorac Surg. 2008 Feb;85(2):S780-4 [18222217.001]
  • [Cites] Radiology. 2004 Jun;231(3):850-7 [15105453.001]
  • [Cites] AJR Am J Roentgenol. 2004 Aug;183(2):361-8 [15269026.001]
  • [Cites] J Thorac Cardiovasc Surg. 1996 Oct;112(4):867-74 [8873711.001]
  • [Cites] J Thorac Cardiovasc Surg. 1997 Jan;113(1):37-49 [9011700.001]
  • [Cites] J Thorac Cardiovasc Surg. 2005 Mar;129(3):639-44 [15746749.001]
  • [Cites] J Thorac Cardiovasc Surg. 2006 Jun;131(6):1236-42 [16733151.001]
  • [Cites] Eur J Cardiothorac Surg. 2006 Jul;30(1):177-83 [16723242.001]
  • [Cites] Thorac Surg Clin. 2006 May;16(2):157-65 [16805205.001]
  • [Cites] Ann Surg Oncol. 2006 Nov;13(11):1529-37 [17009153.001]
  • [Cites] Cancer. 2006 Dec 15;107(12):2873-80 [17096433.001]
  • [Cites] Radiology. 2007 Apr;243(1):268-75 [17392258.001]
  • [Cites] Ann Surg Oncol. 2007 May;14(5):1718-26 [17285398.001]
  • [Cites] J Thorac Cardiovasc Surg. 2007 Oct;134(4):857-64 [17903496.001]
  • [Cites] J Thorac Cardiovasc Surg. 2003 Sep;126(3):732-9 [14502146.001]
  • (PMID = 19324124.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA090440-09; United States / NCI NIH HHS / CA / P50 CA090440; United States / NCI NIH HHS / CA / P50 CA090440-09
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ NIHMS203932; NLM/ PMC2921841
  •  go-up   go-down


95. Nakajima J, Murakawa T, Fukami T, Takamoto S: Is thoracoscopic surgery justified to treat pulmonary metastasis from colorectal cancer? Interact Cardiovasc Thorac Surg; 2008 Apr;7(2):212-6; discussion 216-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is thoracoscopic surgery justified to treat pulmonary metastasis from colorectal cancer?
  • We retrospectively analyzed 143 consecutive patients undergoing pulmonary resection for metastasis from colorectal cancer, either through thoracotomy or thoracoscopy from 1987 to 2005.
  • Patients were divided into two groups, based on whether or not they underwent thoracoscopy (n=72) or open thoracotomy (n=71) at the first pulmonary metastasectomy.
  • Two patients undergoing thoracoscopy died postoperatively (one from pulmonary thromboembolism and one from gastrointestinal bleeding).
  • Factors influencing postoperative recurrence-free or overall survival were multiple pulmonary metastasis and history of liver metastasis by univariate analysis, and multiple pulmonary metastasis, hilar or mediastinal nodal metastasis, larger diameter of the pulmonary metastasis, and surgery by wedge resection by multivariate analysis.
  • Five-year recurrence-free rates after the first pulmonary metastasectomy were 34.4% in thoracoscopy and 21.1% in thoracotomy, respectively (P=0.047).
  • We found no significant difference in the survival rates between the thoracotomy and thoracoscopy groups, even with elimination of the patients with multiple pulmonary metastases in both groups.
  • We suggest that thoracoscopic surgery for pulmonary metastasectomy from colorectal cancer may be justified if the surgical treatment is indicated.
  • [MeSH-major] Colorectal Neoplasms / pathology. Lung Neoplasms / surgery. Patient Selection. Thoracoscopy. Thoracotomy

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18083773.001).
  • [ISSN] 1569-9285
  • [Journal-full-title] Interactive cardiovascular and thoracic surgery
  • [ISO-abbreviation] Interact Cardiovasc Thorac Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


96. Wang Y, Xue TC, Xie XY, Chen Y, Ye SL, Ren ZG: [Relationship between epithelial-mesenchymal transition and lung metastasis in hepatocellular carcinoma]. Zhonghua Wai Ke Za Zhi; 2008 Nov 1;46(21):1624-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Relationship between epithelial-mesenchymal transition and lung metastasis in hepatocellular carcinoma].
  • OBJECTIVE: To evaluate the relationship between epithelial mesenchymal transition (EMT) and lung metastasis in hepatocellular carcinoma.
  • They were classified with non-distance metastasis and lung metastasis depend on the close following up till March 2007.
  • Univariate and multivariate analysis were used for study the relationship between EMT and lung metastasis.
  • RESULTS: Univariate analysis showed that down regulation of E-cadherin, overexpression of fibronectin, cytosolic expression of vimentin, AFP >or= 400 ng/ml, tumor size more than 10 cm, portal vein involvement, poorly differentiated of tumor had close correlation with lung metastasis.
  • Multivariate analysis indicated that overexpression of fibronectin was independent factor for lung metastasis apart from tumor size more than 10 cm, portal vein involvement and poorly differentiated of tumor.
  • CONCLUSION: The results proposed that EMT has close relation with lung metastasis in hepatocellular carcinoma.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Epithelial Cells / pathology. Liver Neoplasms / pathology. Lung Neoplasms / secondary. Stromal Cells / pathology
  • [MeSH-minor] Adult. Aged. Cadherins / metabolism. Cell Differentiation. Female. Fibronectins / metabolism. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Metastasis. Vimentin / metabolism

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19094755.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cadherins; 0 / Fibronectins; 0 / Vimentin
  •  go-up   go-down


97. Tanju S, Ziyade S, Erus S, Bayrak Y, Toker A, Dilege S: Extended resection: is it feasible for pulmonary metastases? Ann Surg Oncol; 2010 Jul;17(7):1912-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extended resection: is it feasible for pulmonary metastases?
  • BACKGROUND: Extended resections may be necessary to achieve tumor-free borders for secondary pulmonary malignancies.
  • This study was performed to analyze the outcomes that result from extended resections of pulmonary metastases.
  • METHODS: Between February 1991 and December 2008, a total of 25 extended pulmonary resections (resection of the chest wall and diaphragm, vascular procedures, sleeve resections, pneumonectomies, atrial resections, and completion pneumonectomies) were performed on 250 patients undergoing 319 metastasectomy procedures.
  • In the subgroup analysis, survival in the extended resections and lobar or sublobar resections groups was not statistically significant (osteosarcoma, P = 0.758; epithelial tumor, P = 0.11).
  • CONCLUSIONS: Extended resections, which can be performed during pulmonary metastasectomies of patients with tumor-free surgical borders, may establish curative benefits, with low rates of mortality and morbidity.
  • [MeSH-major] Lung Neoplasms / secondary. Lung Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Feasibility Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Pneumonectomy. Prognosis. Retrospective Studies. Survival Rate. Young Adult

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20151213.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Tomimaru Y, Yasumoto T, Matsunaga H, Ide Y, Ikeda N, Maruyama K, Yokouchi H, Kinuta T, Murata K: [Two cases of pulmonary metastases from colorectal cancer successfully treated by radiofrequency ablation therapy]. Gan To Kagaku Ryoho; 2007 Nov;34(12):2029-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of pulmonary metastases from colorectal cancer successfully treated by radiofrequency ablation therapy].
  • BACKGROUND: To date, several studies have evaluated an efficacy of radiofrequency ablation (RFA) for liver tumor.
  • However, there are few reports on RFA for metastatic pulmonary tumor.
  • We experienced two patients whose pulmonary metastases from colorectal cancer were treated with RFA.
  • Case 1: A 70-year-old man who had undergone surgery for rectal cancer was followed up in our out-patient clinic.
  • Eleven months after the surgery, a pulmonary metastasis 10 mm in diameter at the left S10 segment was found.
  • So, 17 months after the surgery, RFA was performed for the pulmonary metastasis without any complications.
  • Now, he remains in good condition without any evidence of pulmonary recurrence for 20 months after the RFA.
  • Case 2: A 65-year-old man who had undergone sigmoidectomy for sigmoid colon cancer was followed up in our out-patient clinic.
  • Ten months after the surgery, three pulmonary metastases were found.
  • So, 15 months after the surgery, RFA was performed for the pulmonary metastases.
  • Now, he remains in good condition without any evidence of pulmonary recurrence for 3 months after the RFA.
  • Although a long-term prognosis after RFA remains unclear, it may be an effective and minimally invasive technique for the treatment of pulmonary metastasis.
  • [MeSH-major] Catheter Ablation. Colorectal Neoplasms / pathology. Colorectal Neoplasms / radiotherapy. Lung Neoplasms / pathology. Lung Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / pathology. Liver Neoplasms / radiotherapy. Liver Neoplasms / secondary. Male

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18219888.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


99. Ayarra Jarne J, Jiménez Merchán R, Congregado Loscertales M, Girón Arjona JC, Gallardo Valera G, Triviño Ramírez AI, Arenas Linares C, Loscertales J: [Resection of pulmonary metastases in 148 patients: analysis of prognostic factors]. Arch Bronconeumol; 2008 Oct;44(10):525-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Resection of pulmonary metastases in 148 patients: analysis of prognostic factors].
  • [Transliterated title] Cirugía de metástasis pulmonares en 148 pacientes. Análisis de sus factores pronósticos.
  • OBJECTIVE: To evaluate the prognostic factors for survival in a series of patients who underwent surgery for pulmonary metastases from primary tumors in distinct organs.
  • Patients scheduled for tumorectomy were included provided their primary tumor was controlled and they had no extrathoracic recurrence and adequate cardiorespiratory function.
  • The influence of the following prognostic factors was analyzed: number and diameter of the metastases, lymph node infiltration, complete resection, and, above all, histological type.
  • The factors that affected survival were the number of metastases (P< .05), diameter of the lesions (P< .05), lymph node infiltration (P< .05), complete resection (P< .05), and, above all, histological type (P< .05).
  • CONCLUSIONS: These results suggest that, in the absence of other therapeutic options and contraindications, we should operate on patients in whom the primary tumor is controlled and in whom complete resection can be performed.
  • [MeSH-major] Lung Neoplasms / secondary. Lung Neoplasms / surgery. Pneumonectomy

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19006632.001).
  • [ISSN] 0300-2896
  • [Journal-full-title] Archivos de bronconeumología
  • [ISO-abbreviation] Arch. Bronconeumol.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


100. Neuman HB, Patel A, Hanlon C, Wolchok JD, Houghton AN, Coit DG: Stage-IV melanoma and pulmonary metastases: factors predictive of survival. Ann Surg Oncol; 2007 Oct;14(10):2847-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage-IV melanoma and pulmonary metastases: factors predictive of survival.
  • BACKGROUND: We reviewed a contemporary, single-institution experience to evaluate the natural history of stage-IV melanoma metastatic to the lung and identify factors predictive of survival.
  • METHODS: A search of our prospective database was performed to identify patients with stage-IV melanoma and pulmonary metastases as the initial disease site; only patients seen at our institution prior to developing stage-IV disease and in whom treatment response was available were included.
  • Clinical factors at time of diagnosis of stage IV independently predictive of survival were a solitary pulmonary metastasis (HR 2.7, CI 1.6-4.4, P<0.0005) and absence of extra-pulmonary disease (HR 1.9, CI 1.2-3.1, P = 0.01).
  • Of the patients, 26 (21%) underwent metastasectomy, with a median survival of 40 months compared with 13 months in patients not selected for surgical treatment.
  • CONCLUSIONS: In stage-IV melanoma with pulmonary metastases, a solitary metastasis and absence of extra-pulmonary disease are predictive of survival.
  • While these factors are often present in patients selected for pulmonary metastasectomy, this independently predicts survival.
  • However, response to systemic therapy does not correlate with a survival difference.
  • [MeSH-major] Lung Neoplasms / secondary. Melanoma / secondary. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cohort Studies. Female. Humans. L-Lactate Dehydrogenase / blood. Lung / pathology. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Staging. Pneumonectomy. Prognosis. Prospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2007 Oct;14(10):2696-7 [17674107.001]
  • (PMID = 17680317.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down






Advertisement